Gefitinib (ZD1839)

Catalog No.S1025

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Price Stock Quantity  
USD 191 In stock
USD 147 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Gefitinib (ZD1839) Chemical Structure

Gefitinib (ZD1839) Chemical Structure
Molecular Weight: 446.90

Validation & Quality Control

Cited by 90 publications:

11 customer reviews :

Quality Control & MSDS

Related Compound Libraries

EGFR Inhibitors with Unique Features

  • Pan EGFR Inhibitor

    AZD8931 (Sapitinib) Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.

  • Most Potent EGFR Inhibitor

    Afatinib (BIBW2992) EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.

  • FDA-approved EGFR Inhibitor

    Lapatinib Approved by FDA for breast cancer.

  • Newest EGFR Inhibitor

    CO-1686 (AVL-301) Irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Product Information

  • Compare EGFR Inhibitors
    Compare EGFR Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.
Targets Tyr1173 (NR6W cells) [1] Tyr1173 (NR6wtEGFR cells) [1] Tyr992 (NR6wtEGFR cells) [1] Tyr992 (NR6W cells) [1]
IC50 26 nM 37 nM 37 nM 57 nM
In vitro Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both the high and low-EGFR-expressing cell lines including NR6, NR6M and NR6W cell lines. The phosphorylation sites Tyr1173 and Tyr992 are less sensitive requiring higher concentrations of Gefitinib for inhibition. Gefitinib effectively blocks the phosphorylation of PLC-γ, with IC50 of 27nM, in NR6W cells. The NR6wtEGFR and NR6M cell lines has low levels of PLC-γ phosphorylation but the level in the NR6M cell line is more resistant to inhibition by Gefitinib with IC50 of 43 nM and 369 nM, respectively. Gefitinib inhibits Akt phosphorylations, with IC50 of 220 and 263nM, in the low-EGFR- and -EGFRvIII-expressing cell lines, respectively. Gefitinib in the dose range from 0.1 to 0.5μM significantly facilitates, rather than abrogates, colony formation of NR6M cells. However, at a concentration of 2 μM Gefitinib completely blocks NR6M colony formation. Gefitinib rapidly and in a dose-dependent manner inhibits EGFR and ERK phosphorylation up to 72 hours after EGF stimulation in both the high- and low-EGFR-expressing cell lines. [1] Gefitinib is the monolayer growth of these EGF-driven untransformed MCF10A cells with an IC50 of 20 nM. [2] The combination of Gefitinib (0.2 μM and 0.5 μM) with irradiation lead to a significant growth inhibition in LoVo cells, compared with radiation alone.. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
KBMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\EVWlEPTB;MD6wOVQh|ryPMV[xOlUyPjR5Mx?=
NIH3T3MWPGeY5kfGmxbjDBd5NigQ>?NF\2V3kxNjJizszNMn;QNkBpNYrk[VVITE2VTx?=NHm1[mZKdmirYnn0bY9vKG:oIFXHSkB{fGmvdXzheIVlKGi3bXHuJIVz[kJzIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEG0OEDPxE1?NGi5RVUyPjR6MEK4OC=>
COS7MX7GeY5kfGmxbjDBd5NigQ>?NYjyOGl5QTZizszNMlr2TY5pcWKrdHnvckBw\iCqdX3hckBLSUt{IG[2NVdHKG23dHHueEBmgHC{ZYPz[YQ>MUCxO|E4QDd{Mh?=
A549MlfER5l1d3SxeHnjJGF{e2G7MUO5OkBpNF\wfVNFVVORNGr5ZVlKSzVyPUGzMlU6KM7:TR?=M4nmTFE5OzF|OEC3
K562NYfBdFhsS3m2b4TvfIlkKEG|c3H5M3WwWFk3KGh?NV3qXWNPTE2VTx?=M2Ly[WlEPTB;OT6zOkDPxE1?MVexPFMyOzhyNx?=
MDA-MB-231MnO5R5l1d3SxeHnjJGF{e2G7NHnmRYY6PiCqNFHWVlFFVVORMX7JR|UxRTN4Lk[xJO69VQ>?MUmxPFMyOzhyNx?=
MOLT4MYnDfZRwfG:6aXOgRZN{[Xl?NUnzSo5WQTZiaB?=NHvx[ZJFVVORMWTJR|UxRTF3LkCyJO69VQ>?M1jBbVE5OzF|OEC3
MCF7NY[zfYx3S3m2b4TvfIlkKEG|c3H5NU[wTFJFPTBizszNNHrwWW84OiCqMmW5TWM2OD1zMj6wOUDPxE1?NXyzXJF4OTh5N{G4NVk>
BT474M3O3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYO3NkBpMojPRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCEVES3OEBk\WyuczDveoVz\XiycnXzd4lv\yCHUlLiNkB4cXSqIFXDOVAhd2ZiMD6zJO69VQ>?NXPpdG1TOTlyMki0NlQ>
HN5NYW4cIZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkHDO|IhcA>?NI[5cWpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjOOUBk\WyuczDveoVz\XiycnXzd4lv\yCHR1\SJJdqfGhiRVO1NEBw\iByLkCxJO69VQ>?M1fwTFE6ODJ6NEK0
BA/F3NFnDZ4ZEgXSxdH;4bYMhSXO|YYm=Ml3hO|IhcA>?MoiyR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCHR1\SJGw5PTiUIH31eIFvfCC5aYToJGlEPTBib3[gNE4xOTB6IN88US=>NEiwSW4yQTJ|OUKyPS=>
NIH3T3Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;BNlczKGh?NEmyTWlIem:5dHigbY5pcWKrdHnvckBw\iCvb4Xz[UBPUUhxM2SzJINmdGy|IHX4dJJme3Orbneg[ZJDOiCpZX7lJJdqfGhiSVO1NEBw\iByLkW0JO69VQ>?MnSzNVk3PjV|N{e=
MCF7 MXMXXGeY5kfGmxbjDBd5NigQ>?NYjQR5RmOzBibXnuNIO0[lBKdmirYnn0bY9vKG:oIFLDVnAh\XiycnXzd4VlKHerdHigTWM2OCCxZjCxMlEh|ryPM{Pr[FE6QTN{OU[w
A431NYTnOWM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVKxNEDPxE1?NV;TboJ1PzJiaB?=M13mTWdKPTB;MD61NVQh|ryPM3;UbVE6QTZ7NE[1
A431NGnNVoNMcW6jc3WgRZN{[Xl?MYGwMlEh|ryPNX7RelB4OSCqM1zWVGlvcGmkaYTpc44hd2ZiRVfGMYlv\HWlZXSgSWdHWiCyaH;zdIhwenmuYYTpc44>Mn3LNVk6Pjl2NkW=
A431MXPLbY5ie2ViQYPzZZk>NEHnOVkyODBizszNNFfwdnIyOCCvaX6=Moj4VJJwdG:wZ3XkJIlvcGmkaYTvdpkh[WO2aY\peJkhd2ZiRVfGMYlv\HWlZXSgSWdHWiCyaH;zdIhwenmuYYTpc44>M{XJRVE6QTZ7NE[1
Sf9M2HkfGtqdmG|ZTDBd5NigQ>?M2HVVVExKG2rbh?=MkTsSG1UVw>?M2\oXGlvcGmkaYTpc44hd2ZiRVfGVkBmgHC{ZYPz[YQh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBz\WOncITvdkBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlA{OyEQvF2=MkHkNlAxPTZ2MkW=
NCI-H1975M1WxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\OSVUh|ryPM4roNFczKGh?Mle4TWM2OD16LkK2JO69VQ>?MmfYNlAyPTF4N{C=
NCI-H1975MWTLbY5ie2ViQYPzZZk>NUDNOGJOOTBizszNMYTJcohq[mm2aX;uJI9nKEWJRmKgZZV1d3Cqb4PwbI9zgWyjdHnvci=>NEDUenozODF3MU[3NC=>
NCI-H1975NF\W[XFHfW6ldHnvckBCe3OjeR?=Mmj0NVAh|ryPM3;CO2lvcGmkaYTpc44hd2ZiRWLCRlIh[XW2b4Doc5NxcG:{eXzheIlwdg>?NEDDfmgzODF3MU[3NC=>
NCI-H1975NXj5WZp7TnWwY4Tpc44hSXO|YYm=NXfT[oRLPSEQvF2=M2DodVQ5KGh?NGfnN2ZKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHHzd4V{e2WmIHHzJIFkfGm4YYTpc44hd2ZiY3HzdIF{\S1|M2\MUVIxOTVzNkew
A375MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVX3VFFWPDhiaB?=NHfYXFhKSzVyPUKwMlU2KM7:TR?=Mn;NNlA{ODR3M{e=
SMMC7721MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILZfo41QCCqM1H2[2lEPTB;M{OuNVIh|ryPMVKyNFMxPDV|Nx?=
DU145NX3peFF{S3m2b4TvfIlkKEG|c3H5MW[1JIQ>NELrSZFFVVORNUf0NIVEUUN3ME20Nk4yPyEQvF2=NYLDN3F[OjB2Nk[1OVU>
MIAPaCa2Ml7OR5l1d3SxeHnjJGF{e2G7NWn2WndSPSCmMmXFSG1UVw>?MXPJR|UxRTVyLk[yJO69VQ>?MkG2NlA1PjZ3NUW=
PANC1MljoR5l1d3SxeHnjJGF{e2G7NV;TNFc5PSCmMkDpSG1UVw>?Mme4TWM2OD12MD60NkDPxE1?NXLpTIRsOjB2Nk[1OVU>
PC9M{PSfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jPRWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSWdHWi2mZX\pZ4lmdnRiaIXtZY4hWEN7IHPlcIx{KHerdHigSWM2OCCxZjCwMlAyPyEQvF2=NWf2XoJUOjF{MEi4NFI>
PC9MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3TnN2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sg[5Jwf3SqLYLld4l{fGGwdDDoeY1idiCSQ{mgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKEV5NE\fRVc2OC:WN{mwUUBufXSjboSge4l1cCCHQ{WwJI9nKDdizszNNGHGUZozOTJyOEiwNi=>
PC3NFeyPHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHWzOHoyOCEQvF2=NXrWeoh5PzJiaB?=NFLUO4VFVVORMlS5TWM2OD15LkSg{txOMYOyNVM2OzV2Nh?=
MDA-MB-468NIHXS3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILGO3AyODBizszNMVu0PEBpNVjSfYVTTE2VTx?=NGG4U5RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fS=>Mn31NlE1Ojl4M{K=
Plasmodium falciparumMnu2dWhVWyCycn;mbYxqdmdiZn;yJIlvcGmkaYTvdpMhd2ZiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJJBzd2yrZnXyZZRqd25?NH;acIozOThzN{C0OS=>
NCI-H1993NVHTSVg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPacWNkPzJiaB?=MmLBSG1UVw>?MWjJR|UxRTBwMTFOwG0>MoTBNlE6OTZ2M{O=
NCI-H292M2\YXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjBOFFKPzJiaB?=MkjjSG1UVw>?NX;NT4llUUN3ME2wMlAzKM7:TR?=M1XISVIyQTF4NEOz
A431MoHqT4lv[XOnIFHzd4F6NH63NGQzKGh?MYHEUXNQM4HaSWlvcGmkaYTpc44hd2ZiRVfGVkBxcG:|cHjvdplt[XSrb36gbY4hTUeILYP0bY12dGG2ZXSgbJVu[W5iQUSzNUB4cXSqIFnDOVAhd2ZiMD6wNFEh|ryPMmXlNlIyODFzM{K=
MCF7M{[3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVPDRWY5OTBywrFOwIcwdUx?M4LTVlQ5KGh?NEDIfXdFVVORNYDmOpBWSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJI93\XKneIDy[ZN{cW6pIFXHSnIh\2WwZTD3bZRpKEmFNUCgc4YhOTJwMEWg{txONWLZSYxuOjJzMUmxN|A>
BT474MkDzR5l1d3SxeHnjJGF{e2G7NETifngyOCEQvF2=Mk[1OFghcA>?NX7CN3ZuS3m2b4TvfIlkcXS7IHHnZYlve3Ric3XyeY0ue3Sjco\l[EBpfW2jbjDCWFQ4PCClZXzsdy=>M2\3UlIzOTN6M{C4
MCF7NYfPUItDS3m2b4TvfIlkKEG|c3H5MXGxNEDPxE1?M1;0R|Q5KGh?MYjDfZRwfG:6aXPpeJkh[WejaX7zeEB{\XK3bT3zeIFzfmWmIHj1cYFvKE2FRkegZ4VtdHNib4\ldk1mgHC{ZYPzbY5oKEW{YlKyJINmdGy|MkXHNlIyOzh|MEi=
HCC827M1fnUWtqdmG|ZTDBd5NigQ>?M1LINVAvOTJ3IN88US=>MYGyOEBpM1;GZ2ROW09?NHvXdHFKdmirYnn0bY9vKG:oIFXHSnIh\GWuIFW3OFYuSTd3MDDteZRidnRiWUGwOlgh[XW2b4Doc5NxcG:{eXzheIlwdg>?NVXRbIlUOjJ|M{mzOFI>
HCC827MkPlT4lv[XOnIFHzd4F6MUWwMlEzPSEQvF2=MlrHNlQhcA>?NVzKNYx[TE2VTx?=NULsT486UW6qaXLpeIlwdiCxZjDFS2ZTKGSnbDDFO|Q3NUF5NUCgcZV1[W62LX3l[IlifGWmIFXyb{BxcG:|cHjvdplt[XSrb36=MX6yNlM{QTN2Mh?=
HCC827MXnLbY5ie2ViQYPzZZk>M335VlAvOTJ3IN88US=>NWX6W4FsOjRiaB?=MlrFSG1UVw>?MYTJcohq[mm2aX;uJI9nKEWJRmKg[IVtKEV5NE[tRVc2OCCvdYThcpQudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>?MVKyNlM{QTN2Mh?=
A431MlvyT4lv[XOnIFHzd4F6MYWxNFAh|ryPMmHYN|AhdWmwMmD0TY5pcWKrdHnvckBw\iCHR1\SJIRmemm4ZXSg[pJwdSCqdX3hckBCPDNzIHPlcIwhdWWvYoLhcoUh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxd2y7LVfseU1VgXJicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCxMlA5KM7:TR?=NXPaRW1vOjJ4OUi3PFI>
H460NIjHWoNEgXSxdH;4bYMhSXO|YYm=M{O3eFczKGh?M4T4WGlEPTB;NT61PUDPxE1?M1vlNFIzPzJ5NES5
HT-29MYPDfZRwfG:6aXOgRZN{[Xl?M3rnT|czKGh?NU\wPIIxUUN3ME2zMlM3KM7:TR?=Mki4NlI4Ojd2NEm=
SGC7901M1npOWN6fG:2b4jpZ{BCe3OjeR?=MorYO|IhcA>?MYjJR|UxRTFyLkK2JO69VQ>?M4LJbFIzPzJ5NES5
A498NILW[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3f5UWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUS5PEBk\WyuczDlfJBz\XO|aX7nJGVITlJiYX7kJHNTSyC5aYToJGlEPTBib3[gPE43KM7:TR?=MonSNlI5OTh6NEi=
Calu3M1O0OGN6fG:2b4jpZ{BCe3OjeR?=NVXYT2VMOTBizsznM41NMl\6O|IhcA>?NWmwUZlJUUN3ME2xMlYh|ryPM2Djd|I{OTF4MU[4
FADUNInvXXREgXSxdH;4bYMhSXO|YYm=NIXiUo8yOCEQvHevcWw>NVn1NGFkPzJiaB?=MYXJR|UxRTBwMEWg{txOM1S2N|I{OTF4MU[4
HCC827MY\DfZRwfG:6aXOgRZN{[Xl?NX:5VGdTOTBizsznM41NNULMeoZsPzJiaB?=NFrhdpdKSzVyPUCuNFAyPSEQvF2=M4raU|I{OTF4MU[4
PC9MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWexNEDPxGdxbVy=NUjCSGMxPzJiaB?=NHjuUHhKSzVyPUCuNFAyPCEQvF2=Ml3QNlMyOTZzNki=
Sf9MVvLbY5ie2ViQYPzZZk>MX6xJIg>MUfEUXNQMYjJcohq[mm2aX;uJI9nKGi3bXHuJGdUXC22YXfn[YQhTUeIUjDMPFM1WiCvdYThcpQh\XiycnXzd4VlKHerdHigTWM2OCCxZjCwMlAyPSEQvF2=MXGyN|YyOTZ7MR?=
16HBE14o-NYn1N45nS3m2b4TvfIlkKEG|c3H5MVmxNEDPxE1?NH\lbJE4OiCqMUXEUXNQNWPGVZZbS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hOT[KQlWxOI8uKGOnbHzzJIhiemKxcnnu[{B4cWymIIT5dIUhTUeIUjDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMUKuO|Eh|ryPMYSyN|Y3QDR2MR?=
NCI-H1975NVmyU4s5S3m2b4TvfIlkKEG|c3H5NHjTN44yOCEQvF2=MVG3NkBpNGDm[ohFVVORMYDDfZRwfG:6aXPpeJkh[WejaX7zeEBo\W[rdHnubYIuemW|aYP0ZY51KGi3bXHuJG5EUS2KMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIIfpeIghUUN3MDDv[kA3NjlzNzFOwG0>MluwNlM3Pjh2NEG=
16HBEM{jvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3jkSlczKGh?M1fScGROW09?Ml[4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiBzNljCSUBk\WyuczDlfJBz\XO|aX7nJJdqdGRidInw[UBGT0[UIIfpeIghUUN3MDDv[kAyNjZyMTFOwG0>M{HaXVI{Pzl{M{G4
16HBEMlvlSpVv[3Srb36gRZN{[Xl?NWjSe5kyOTByIN88US=>NYj3UXZyOTVyIH3pci=>M2rkb2ROW09?MkOxTY5lfWO2aX;uJI9nKG6rdILpZ{BwgGmmZTDwdo9lfWO2aX;uJIlvKGi3bXHuJFE3UEKHIHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFXHSnI>NHXTOngzOzd7MkOxPC=>
A549NUThdFBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvrVI04OiCqMkHJSG1UVw>?MkfuRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDD3bYxlKHS7cHWgSWdHWi:tLWLhd{Bl\XCnbnTlcpQhcHWvYX6gRVU1QSClZXzsd{B4cXSqIFnDOVAhd2ZiND62NlYh|ryPMnuxNlM4QTJ|MUi=
SH-SY5YMYHDfZRwfG:6aXOgRZN{[Xl?NFX5W3g4OiCqMVvJR|UxRTF6LkKxJO69VQ>?MoTsNlM5PzF7MEm=
LoVoMX;LbY5ie2ViQYPzZZk>M3vyVlIhKGh?MYrEUXNQMoPsTY5pcWKrdHnvckBw\iCHR1\SJJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yNkKg{txONVLIcHZKOjN7M{C5PVQ>
PC9MXrLbY5ie2ViQYPzZZk>M4XVZ|IhcA>?MnLCSG1UVw>?M1jBU2lvcGmkaYTpc44hd2ZiRVfGVkBmgG:wIEG5JIRmdGW2aX;uJIFkfGm4YYTpcochdXW2YX70JJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDQR|kh[2WubIOge4l1cCCLQ{WwJI9nKDBwMEC4O{DPxE1?MojYNlM6OzB7OUS=
HCC827NFrtZ2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoDlO|IhcA>?MULJR|UxRTBwMEGyJO69VQ>?NHG4b3EzOzl5M{G2PC=>
A549M4nxN2tqdmG|ZTDBd5NigQ>?NUDsdIJHOSEQvF2=MWOxJIg>NVTqfpNETE2VTx?=MWXJcohq[mm2aX;uJI9nKEWJRmKgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wN|k6KM7:TR?=MYSyN|k5QDN3NB?=
A549Ml;rSpVv[3Srb36gRZN{[Xl?NIjuNFQyKM7:TR?=MW[xJIg>NWP2OXlFTE2VTx?=M1mxUWNmdGy3bHHyJJVxfGGtZR?=M{jyTlI{QTh6M{W0
HCC827NUOyRYY3U2mwYYPlJGF{e2G7NH3xSm8xNjVizszNMVqyJIg>M3TZdWROW09?NXzkdWxoUW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCpZX\peIlvcWJvcnXzbZN1[W62IHj1cYFvKEiFQ{iyO{Bk\Wyucx?=NEPYV|YzOzl7M{OyPC=>
HCC827NVP4ZXZ7TnWwY4Tpc44hSXO|YYm=MofWNE42KM7:TR?=MYKyJIg>M2ezRmROW09?M2XDOWlvcGmkaYTpc44hd2ZiYz3N[ZQheGixc4Doc5J6dGG2aX;uJIlvKGenZnn0bY5q[i2{ZYPpd5RidnRiaIXtZY4hUEOFOEK3JINmdGy|NHPUfokzOzl7M{OyPC=>
HCC827Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7wd|cyOCEQvF2=MmHYO|IhcA>?M3;ybWROW09?MYnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHfl[ol1cW6rYj3z[Y5{cXSrdnWgbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIFW3OFYhfG9iQUe1NEBl\WyndHnvckB4cXSqIFnDOVAhd2ZiMD6wNFU5OSEQvF2=NVzFcpFlOjRyNUO2O|Q>
A431MUXLbY5ie2ViQYPzZZk>M3;pbVExOCEQvF2=MXizNEBucW5?MkjGTY5pcWKrdHnvckBw\iCHR1\SJIlvKHOqZXSgcYVu[nKjbnWgeoV{cWOuZYOge4l1cCCLQ{WwJI9nKDFwMTFOwG0>NFvESmkzPDB7NESzNi=>
BCRP-MDCK2Moi3SpVv[3Srb36gRZN{[Xl?NWfQfWNiOS56IN88US=>MWi3NkBpNYrTToVqTE2VTx?=MmfETY5kemWjc3Wgc4YheGyjc33hJI1mdWK{YX7lJIV5eHKnc4Ppc44hd2ZiQlPSVEBmgHC{ZYPzbY5oKHKncH;yeIVzKGenbnWgS2ZRMXiyOFE5PDJzMx?=
BCRP-MDCK2M1rNVmZ2dmO2aX;uJGF{e2G7MknuNU45KM7:TR?=Mm\QO|IhcA>?M3nnNWROW09?M4rOfnJm\HWldHnvckBw\iCybHHzcYEhdWWvYoLhcoUh\XiycnXzd4lwdiCxZjDCR3JRKGW6cILld5NqdmdicnXwc5J1\XJiZ3Xu[UBITlB?M3:zS|I1OTh2MkGz
MDCKNYnqVodkS3m2b4TvfIlkKEG|c3H5MkHaO|IhcA>?NX3vNXUyTE2VTx?=MWLHTVUxRTFwNEWg{txOMYWyOFE5PDJzMx?=
MDCK2NVnpSWVJTnWwY4Tpc44hSXO|YYm=NHrERooyNjhizszNMVS3NkBpM4jZWmROW09?M{TGemlvcGmkaYTpc44hd2ZiaIXtZY4hSkOUUDDlfJBz\XO|ZXSgZZN{\XO|ZXSgZZMhUG:nY3jzeEA{OzN2MjDhZ4N2dXWuYYTpc44hf2m2aDDJR|UxKG:oIEOuNVkh|ryPMUWyOFE5PDJzMx?=
A431NGLJd4VEgXSxdH;4bYMhSXO|YYm=NX3UXYh2PzJiaB?=NGrMOIVFVVORNFXqW5hEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPDNzIHPlcIx{KGW6cILld5NqdmdiRVfGVkB4cXSqIFnDOVAhd2ZiMD61OUDPxE1?NGfj[lAzPDRzMUGyNy=>
Calu3MUHDfZRwfG:6aXOgRZN{[Xl?MYG3NkBpM{XRSWROW09?NHjadFREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBE[Wy3MzDj[YxteyCneIDy[ZN{cW6pIFjFVlIhf2m2aDDJR|UxKG:oIECuPVkh|ryPMXeyOFQyOTF{Mx?=
KBNFSwZWFMcW6jc3WgRZN{[Xl?MYCxNEDPxE1?NEfB[20yKGh?M4XXfWROW09?NWDSSFd7UW6qaXLpeIlwdiCxZjDFS2Yue3SrbYXsZZRm\CCjdYTvdIhwe3Cqb4L5cIF1cW:wIH;mJGVITlJid3n0bEBKSzVyIH;mJFAvODJ3IN88US=>MnjNNlQ1OTFzMkO=
BEAS2BM1v6NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUO1NEDPxE1?NYHGRpJtPzJiaB?=MkjNSG1UVw>?MYLJR|UxRTF|Lkm0JO69VQ>?M3XRTlI1PjB5NUmx
NCI-H1975MVTGeY5kfGmxbjDBd5NigQ>?NVW1XI1yOTByIN88US=>M{C0cVE2OCCvaX6=NI\DXWJFVVORM4PsOWlv\HWldHnvckBw\iCQTzDwdo9lfWO2aX;uJIlvKGi3bXHuJG5EUS2KMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4Vk9VPzlyTTDteZRidnR?Mn\4NlQ3ODd3OUG=
HelaM2DW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2TTNlI1KGh?NUn5flFJTE2VTx?=Ml3STWM2OD1{Lk[3JO69VQ>?NI\Y[mczPDd|MUK4NS=>
HepG2NU\NRm92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV6yOEBpM1mydGROW09?MU\JR|UxRTZwNEKg{txOMWWyOFc{OTJ6MR?=
Sf9Mm\aT4lv[XOnIFHzd4F6MWCxNEBucW5?MXvEUXNQMn;sTY5pcWKrdHnvckBw\iCjdYTvdIhwe3Cqb4L5cIF1cW:wIH;mJJJm[2:vYnnuZY51KGircz30ZYdo\WRiRVfGVkAp[W2rbn:gZYNq\CB4NEWtNVE5PiliZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAxNjB{IN88US=>MXeyOFc{OTJ6MR?=
SW620MWTDfZRwfG:6aXOgRZN{[Xl?NHHuWJA1QCCqNULLXXRqTE2VTx?=MkfPTWM2OD1{OD6yJO69VQ>?MkT4NlQ6ODB3OUS=
HCC827NVHabFFKTnWwY4Tpc44hSXO|YYm=NXfIb5RvOC53IN88US=>NVGwTYZtOiCqM{XYbmROW09?Mofq[I9meyCwb4SgbY5pcWKrdDDjMW1mfCCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEGNVDDwbI9{eGixconsZZRqd25?NITxN5QzOzl7M{OyPC=>
HCC827MmX6SpVv[3Srb36gRZN{[Xl?NGDaOlIxNjVizszNNVrNZlV4OiCqMVPEUXNQMkPt[I9meyCwb4SgbY5pcWKrdDDjMW1mfCCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHB2ND:0NkBxcG:|cHjvdplt[XSrb36=NY\TPJdWOjN7OUOzNlg>
HCC827MX7DfZRwfG:6aXOgRZN{[Xl?MWewMlUh|ryPM4LJfFczKGh?NYDPbJNtTE2VTx?=NHnzfpdp[XNibn:gZ5l1d3SxeHnjbZR6NXv1VoJzOjN7OUOzNlg>
NCI-H1975NGfuR5pHfW6ldHnvckBCe3OjeR?=NWW5eFB{OTBizszNNH:0VXM5KGh?M4jUdmROW09?NWDqfoRO\G:nczDuc5QhcW6qaXLpeIkhTUeIUjDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iRWLLJJBpd3OyaH;yfYxifGmxbh?=M1nJdFI{OTF4MU[4
A431NVGx[4NGU2mwYYPlJGF{e2G7MnLrNUDPxE1?M1TDd|EhcA>?MXLEUXNQMWLoZZMhdm9iaYLy[ZZmenOrYnzlJIlvcGmkaYTpc44hd2ZiRVfGVkBifXSxcHjvd5Bpd3K7bHH0bY9vM3;XW|I1QTByNUm0
LNCaPM3fZUWZ2dmO2aX;uJGF{e2G7NUDGOZJ5OTBizszNNIDvPXYzcCCxcjC0JIg>MmTPSG1UVw>?MWrkc4V{KG6xdDDpcohq[mm2IHH1eI9xcG:|cHjvdplt[XSrb36gc4YhcW2vdX7vdJVzcW[rZXSg[oxi\y22YXfn[YQhSm26IHHzd4V{e2WmIHHzJIlv[2:{cH;yZZRqd25ib3[gX|MzWF2DVGC=NUPnc3Z{OTh4NkezNVI>
H1975MkHiT4lv[XOnIFHzd4F6M3vES|Eh|ryPMU[yOEBpNIPYdGtFVVORMlHa[I9meyCwb4SgbY5pcWKrdDDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBJOTl5NTDj[YxteyCqYYLic5JqdmdiRVfGVkBNQDV6Uj;UO|kxVSCvdYThcpQ>MVmyOFYxPzV7MR?=
H1975NYTnU5FSTnWwY4Tpc44hSXO|YYm=M2XwS|Eh|ryPMmG5NlQhcA>?MWXEUXNQNFTWflJld2W|IH7veEBqdmirYnn0JGVTUyCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFc6OE1?M1vMRlI1PjB5NUmx
HCC827MnPoT4lv[XOnIFHzd4F6MXuwMlEyKM7:TR?=MVqxJIg>NYPifW1QTE2VTx?=M1f4OYhieyCwbzDpdpJmfmW{c3nicIUhcW6qaXLpeIlwdiCxZjDFS2ZTKGG|c3Xzd4VlKGG|IILlZ493\XK7IH;mJGVITlJiYYX0c5Bpd3OyaH;yfYxifGmxbh?=MUCyOFEzPDh7OB?=
H1975NHq5SFRMcW6jc3WgRZN{[Xl?MXywMlM{KM7:TR?=MlfONkBpMUDEUXNQNIX6PGVld2W|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2g[I92[mynIH31eIFvfCCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hSUuWIIDoc5NxcG:{eXzheIlwdg>?MUeyOFEzPDh7OB?=
H1975M3;GdmtqdmG|ZTDBd5NigQ>?NFPNeIgxNjN|IN88US=>NVriTHBWOiCqMnrUSG1UVw>?MYTkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gSXJMKHCqb4PwbI9zgWyjdHnvci=>M2O1UFI1OTJ2OEm4
H1975M4S2VmtqdmG|ZTDBd5NigQ>?MVuwMlM{KM7:TR?=NX\Y[ldqOiCqM3rQbmROW09?MWLkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEBxcG:|cHjvdplt[XSrb36=M3v3O|I1OTJ2OEm4
H1975NGfpdldMcW6jc3WgRZN{[Xl?M3j5NlAvOTJ3IN88US=>MorYNlQhcA>?MUHEUXNQM{jaNIRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDteZRidnRiWUGwOlgh[XW2b4Doc5NxcG:{eXzheIlwdg>?M1voO|IzOzN7M{Sy
H1975NHe0[o1McW6jc3WgRZN{[Xl?MnLrNE42KM7:TR?=Mn3CNlQhcA>?NF\USo5FVVORNYLWW3BF\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJI12fGGwdD3t[YRq[XSnZDDFdosheGixc4Doc5J6dGG2aX;uMViyNlM{QTN2Mh?=
H1975NUDocmp4U2mwYYPlJGF{e2G7MX2wMlUh|ryPM3vuT|I1KGh?MnfTSG1UVw>?MUPkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51NW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25?M3T6UFIzOzN7M{Sy
MIAPaCa2MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVXiT4pnOi53IN88US=>NH3icXg4OiCqM4i3VWROW09?NHfaV3Fp[XNibn:g[5Jwf3SqIHnubIljcXSrb36=MlTDNlA1PjZ3NUW=
MIAPaCa2NH;Bc5BEgXSxdH;4bYMhSXO|YYm=M1XDPFEh|ryPM4XhTVExKGR?NULB[VUyTE2VTx?=MXroZZMhdm9iY4n0c5RwgGmlaYT5JIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJINwdG:weTDmc5Ju[XSrb36=M17sdVIxPDZ4NUW1
MIAPaCa2M{\yOWFxd3C2b4Ppd{BCe3OjeR?=NHj0UlYyOCEQvF2=MUKyOIghd3JiNEigbC=>MXvEUXNQNED1VWFld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nzMnLVNlA1PjZ3NUW=
MIAPaCa2MWXBdI9xfG:|aYOgRZN{[Xl?MVOyNEDPxE1?NEniVlUzPCCqMnrwSG1UVw>?NIXXS5Vld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W|c3XkJIF{KGOjc4Dhd4UhOyCjY4TpeoF1cW:wNVO3XW0xOjB2Nk[1OVU>
EoL-1Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jncmlEPTB;NT6xO{BvVQ>?MUfTRW5ITVJ?
NCI-H720NH:wdGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHxb2FKSzVyPUK2MlkzKG6PMoPEV2FPT0WU
NCI-SNU-5NIDyZnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mle3TWM2OD1{OD6xPUBvVQ>?Ml7lV2FPT0WU
EW-3NFfOXWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUjnbWZGUUN3ME20Ok4xPCCwTR?=NX;TeIh2W0GQR1XS
HCC2218NILRPXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGL1bZBKSzVyPUWwMlU6KG6PMVfTRW5ITVJ?
HuO-3N1NGq2WIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTV4LkC5JI5ONXS2N2ZuW0GQR1XS
DBMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzHXlBuUUN3ME22NE46PiCwTR?=MYDTRW5ITVJ?
HSC-4MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVXJR|UxRTZzLkWzJI5OMXvTRW5ITVJ?
DOKNGjJZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nmTWlEPTB;OUOuOlIhdk1?MnrUV2FPT0WU
H9M33a[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1GwfGlEPTB;MUO3MlIhdk1?NWjjfpVOW0GQR1XS
NCI-H292MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIjRVlRKSzVyPUG2Nk43PiCwTR?=MWLTRW5ITVJ?
HSC-2M1XQfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M33wdmlEPTB;MU[1MlU4KG6PNFriN|BUSU6JRWK=
LU-65NVLocIpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTF4Nj62NUBvVQ>?MXnTRW5ITVJ?
BV-173NVP6dFR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\NOGlEPTB;MUi2MlU2KG6PM1HaVnNCVkeHUh?=
LB2241-RCCMmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTF7ND65N{BvVQ>?M2rMSnNCVkeHUh?=
KG-1M1rhWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXGVmxtUUN3ME2yNFQvOzRibl2=M{jKfnNCVkeHUh?=
CHL-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MofNTWM2OD1{MEiuOVEhdk1?Mkn3V2FPT0WU
KYSE-140MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLLTWM2OD1{MEmuPVYhdk1?M2r4UHNCVkeHUh?=
DU-145MlTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTJzOT6wOEBvVQ>?MUXTRW5ITVJ?
EW-13MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG\vRWxKSzVyPUKyOU4yKG6PM4rnZ3NCVkeHUh?=
KYSE-450MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTJ2Nz65NkBvVQ>?NH\iZnNUSU6JRWK=
CAL-72Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTJ4OD63N{BvVQ>?M3OxZ3NCVkeHUh?=
MEG-01MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTme4NKSzVyPUK3Ok44PiCwTR?=MWHTRW5ITVJ?
HCE-TMkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHrTWM2OD1{N{muO|khdk1?M2H0fnNCVkeHUh?=
NCI-SNU-1MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmXkTWM2OD1{OEOuN|Ihdk1?NXrxXWxWW0GQR1XS
CAL-27MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlfKTWM2OD1{OEmuNFghdk1?NILG[npUSU6JRWK=
BALL-1M1:0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG\VbWdKSzVyPUK5O{41OiCwTR?=NFHNOFFUSU6JRWK=
SBC-1MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEjSSJRKSzVyPUOwO{44QSCwTR?=NHvM[JBUSU6JRWK=
CAL-54NGK4T5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nQOmlEPTB;M{GxMlI{KG6PNGnScFlUSU6JRWK=
TI-73M4HTOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;ZV5pEUUN3ME2zNVIvPzVibl2=MlXXV2FPT0WU
P12-ICHIKAWAMofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTN{OD6wOkBvVQ>?MX\TRW5ITVJ?
ACHNMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnrN5pKSzVyPUOzNU41KG6PNH\NWnZUSU6JRWK=
PC-14NV;RU2U5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjj[IJKSzVyPUOzN{41OSCwTR?=NX:5RWF6W0GQR1XS
HCC1806MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGn5[5RKSzVyPUOzO{42OSCwTR?=M2XFfnNCVkeHUh?=
SK-MEL-24M1ruSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{nnNmlEPTB;M{O3Mlg4KG6PMX;TRW5ITVJ?
A4-FukM17vTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTN3MD6wNkBvVQ>?NGTFeW9USU6JRWK=
ECC10Mlm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnvRTWM2OD1|NUKuPVYhdk1?MWjTRW5ITVJ?
KASUMI-1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWO4WIZMUUN3ME2zOlYvPzNibl2=NHfNbodUSU6JRWK=
CAL-33MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYXKUFBMUUN3ME2zO|AvQSCwTR?=NHO3NINUSU6JRWK=
MDA-MB-175-VIIM{TKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jXOGlEPTB;M{e4Mlg5KG6PM1iz[HNCVkeHUh?=
NUGC-3NUXQdZFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jEOGlEPTB;NECxMlgyKG6PNEGzfXlUSU6JRWK=
KY821MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljWTWM2OD12MEiuOVchdk1?NHe5dGpUSU6JRWK=
CTB-1NYfQXXBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XDemlEPTB;NEK0MlQhdk1?Mme0V2FPT0WU
DoTc2-4510NGPoSFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUjrc5JWUUN3ME20OFIvOTJibl2=NHzVTVFUSU6JRWK=
EFO-27NEDFSHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TlfWlEPTB;NEW0Mlc1KG6PMWLTRW5ITVJ?
BPH-1NYjr[Ih1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4Hnc2lEPTB;NEmxMlE3KG6PNV;vN5FDW0GQR1XS
KYSE-270Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkLSTWM2OD12OUiuOlUhdk1?M13DWnNCVkeHUh?=
HO-1-N-1MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTVyOT6yOUBvVQ>?NWXNeZh2W0GQR1XS
SK-MEL-1NWDj[VU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MknKTWM2OD13MUCuPVkhdk1?NXzJ[YFzW0GQR1XS
MOLT-13NEe0RoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3e3WGlEPTB;NUG0MlgzKG6PMm\mV2FPT0WU
TK10NUDBWIFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NESxXlJKSzVyPUWxOU4yOSCwTR?=Ml\JV2FPT0WU
HNNVLXN3VvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTVzNz6zPEBvVQ>?MXfTRW5ITVJ?
SCC-15MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETTWnRKSzVyPUWyOU43QCCwTR?=NH;0R4VUSU6JRWK=
NCI-H358NVnPcZB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnO5TWM2OD13MkeuOlYhdk1?NVvh[ZFrW0GQR1XS
KYSE-180M3\zfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{j1S2lEPTB;NUOwMlYzKG6PNECxbFVUSU6JRWK=
NCI-H82NW\ZbYhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\3TWM2OD13NECuOUBvVQ>?NYT4OI9bW0GQR1XS
NB7NWPJXYJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTV2Nj6zNkBvVQ>?NYrZSYlpW0GQR1XS
DSH1MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWrnepRpUUN3ME21OlYvQDhibl2=NH\QcVBUSU6JRWK=
RS4-11NHPObpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnK4TWM2OD13NkiuOVkhdk1?M1X5eHNCVkeHUh?=
CANNYrFXJlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH3pR|hKSzVyPUW4NE44PiCwTR?=Mk\DV2FPT0WU
Ca9-22M4jCeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjNNmVKSzVyPUW4PE43PCCwTR?=M4DaTnNCVkeHUh?=
CAL-39MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4TU[2lEPTB;NUm2MlMhdk1?MkLEV2FPT0WU
NCI-H1623MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWjEdJg2UUN3ME21PVkvOzZibl2=M1zLSXNCVkeHUh?=
FADUM4PYNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDJNpRKSzVyPU[wOE43QSCwTR?=NID3dXhUSU6JRWK=
NB69Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTIeW8yUUN3ME22NVQvOzVibl2=NU[5bY5[W0GQR1XS
Ramos-2G6-4C10NXr5U3NoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHHTHI{UUN3ME22NlEvPDZibl2=NWXu[JNvW0GQR1XS
LB1047-RCCMoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDCT3RKSzVyPU[yOU4zQSCwTR?=M3zaUnNCVkeHUh?=
MV-4-11M2HoUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXfsenYxUUN3ME22NlcvPyCwTR?=MXvTRW5ITVJ?
DBTRG-05MGNHnEdJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3ETWM2OD14M{KuNlghdk1?M1;MSnNCVkeHUh?=
ME-180M{LtZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTZ|Mj65JI5ONGiy[mhUSU6JRWK=
NBsusSRNHrGU3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmH1TWM2OD14NE[uOVIhdk1?NHjEUmFUSU6JRWK=
COR-L105NU\GWYd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1HJbGlEPTB;Nk[yMlU{KG6PM1m5WnNCVkeHUh?=
ETK-1MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFz1OXBKSzVyPU[2Nk42QSCwTR?=MWnTRW5ITVJ?
L-363NEPZUYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2TNd2lEPTB;NkexMlk1KG6PNETkVndUSU6JRWK=
LU-134-ANWXaRY9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFTTb|ZKSzVyPUexPU4xQSCwTR?=Mn3mV2FPT0WU
NCI-H1770M1ftZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk[2TWM2OD15MkKuOEBvVQ>?NIXq[I9USU6JRWK=
HAL-01NG[2S2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInHV|RKSzVyPUezOE44OSCwTR?=NVL5W3NNW0GQR1XS
COLO-684NE\kTYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGPBb2FKSzVyPUe1N{4xOSCwTR?=M1SzRXNCVkeHUh?=
TE-6NVTkeZp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTd4ND6zNUBvVQ>?NYToe5E6W0GQR1XS
A431NHXuOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTd6MD6wOEBvVQ>?NIjwUWhUSU6JRWK=
LU-135NFrzbFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnnxTWM2OD15OEOuNFMhdk1?NXrRWFZHW0GQR1XS
EC-GI-10MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHLEclJKSzVyPUe4PE42OiCwTR?=NGHuUIVUSU6JRWK=
TE-12NYe3R3dsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HaWmlEPTB;OEKxMlEyKG6PNYnXcJQzW0GQR1XS
LoVoM2CxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\zWWZPUUN3ME24OVkvODZibl2=NH6xO3BUSU6JRWK=
23132-87M4j5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTh4ND6yPEBvVQ>?MYDTRW5ITVJ?
AU565NYjYPHlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHhcpZwUUN3ME24OlkvPiCwTR?=Mnf5V2FPT0WU
DELMnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MknRTWM2OD16N{euOlUhdk1?M2fwcXNCVkeHUh?=
COR-L88Mmm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHleZdKSzVyPUi4Nk4zPiCwTR?=M4njWHNCVkeHUh?=
NCI-H2126MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTh6Mj64N{BvVQ>?NHG2XXlUSU6JRWK=
CAPAN-1MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MofmTWM2OD16OEOuNlkhdk1?M3HEZ3NCVkeHUh?=
BT-474NESwenBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW\WTIZUUUN3ME25N|gvOTRibl2=NWT6[XltW0GQR1XS
BHYM1j1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDVNYFKSzVyPUm3OU41QCCwTR?=NGTZe|FUSU6JRWK=
HT-3M2S0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkXsTWM2OD17OEKuOFEhdk1?NGnNWHJUSU6JRWK=
SK-NEP-1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3LPcGlEPTB;OUi5MlQ1KG6PMmLDV2FPT0WU
MS-1M1q0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfK[VFKSzVyPUm5OE43QSCwTR?=NEnBNGdUSU6JRWK=
DOHH-2MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\LdHNKSzVyPUGuNFAxOjFizszNMlPiV2FPT0WU
NCI-H1304M4D6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV7zcG91UUN3ME2xMlAyPjR|IN88US=>Moi1V2FPT0WU
EM-2MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTFwMEOwNVYh|ryPNXjmbGZZW0GQR1XS
MHH-PREB-1NW\Lc3M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2W0S2lEPTB;MT6wPFQ2OSEQvF2=MmfPV2FPT0WU
KU-19-19NF7IcphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXGySHNFUUN3ME2xMlA5PTRzIN88US=>NInBS2NUSU6JRWK=
NCI-H1648NXnJTFZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV3JR|UxRTFwMUC2NVYh|ryPM{m4ZnNCVkeHUh?=
MKN1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{ntOmlEPTB;MT6yNVk5PyEQvF2=NGXCW4ZUSU6JRWK=
SNU-449NXHoZ4xWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFrOTZdKSzVyPUGuNlIzODhizszNM1XLWnNCVkeHUh?=
OAW-42MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTFwMke4NlUh|ryPMo\BV2FPT0WU
769-PMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTFwMke5NVgh|ryPMXnTRW5ITVJ?
SW1088Mo\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\sTWM2OD1zLkK5OlA4KM7:TR?=NG\NNlJUSU6JRWK=
GCIYMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\CTWM2OD1zLkOwNVMzKM7:TR?=MoD3V2FPT0WU
CTV-1NXXTR4VNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjjR5F7UUN3ME2xMlMxQCEQvF2=NFPiW3RUSU6JRWK=
NCI-H1092MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTFwM{C4OUDPxE1?MX;TRW5ITVJ?
NKM-1NEXMemNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2DiS2lEPTB;MT6zNlU6PyEQvF2=NFXlTIZUSU6JRWK=
NCI-H1650NE[4PGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4Pxb2lEPTB;MT6zN|Q5OiEQvF2=M2K1e3NCVkeHUh?=
SW954MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTFwM{SwOFgh|ryPMofmV2FPT0WU
SW48NH\ENlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTFwM{[2NVgh|ryPMYTTRW5ITVJ?
SK-N-DZM1zUWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPCW2FKSzVyPUGuN|Y6PDdizszNMnS0V2FPT0WU
KMOE-2NWfWcpJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTFwM{m4NVUh|ryPMoDLV2FPT0WU
NB5MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTFwNEC4PVQh|ryPNEDVe3RUSU6JRWK=
CCRF-CEMNGnXfYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDvTWM2OD1zLkSxNVEh|ryPNEfQdYNUSU6JRWK=
RH-1MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTFwNEGxN|Yh|ryPNWDnN3BtW0GQR1XS
NCI-H526MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPZSpZKSzVyPUGuOFM5OjZizszNMV7TRW5ITVJ?
697M4rORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXKx[ZE{UUN3ME2xMlQ1OTB2IN88US=>Mn7QV2FPT0WU
J82MmDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEPZR5hKSzVyPUGuOFU4PjZizszNMmKzV2FPT0WU
BE-13Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrwT3BKSzVyPUGuOVA3PzFizszNMoDCV2FPT0WU
SASMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HmUGlEPTB;MT61NVYzOiEQvF2=M1jOfXNCVkeHUh?=
SCC-25NX\ZN4RNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTFwNUKzNlIh|ryPMmG1V2FPT0WU
LAMA-84NWOzTYtDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3TFWWlEPTB;MT61N|gyPSEQvF2=MVzTRW5ITVJ?
HSC-3Mmn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXvTWM2OD1zLkW0N|gh|ryPMnjwV2FPT0WU
BT-549MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlfRTWM2OD1zLkW4O|Q4KM7:TR?=NH;vSVZUSU6JRWK=
ML-2M1f2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTFwNkSwNlkh|ryPNWLKfo56W0GQR1XS
BB30-HNCMlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\pTWM2OD1zLk[4PVczKM7:TR?=M4PXOHNCVkeHUh?=
PANC-03-27NVTuTVlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWO3bVFOUUN3ME2xMlcxOTN7IN88US=>M3PMNXNCVkeHUh?=
COLO-678NHHLb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTFwN{O0OFQh|ryPNY[1WHg4W0GQR1XS
NCI-H1666NVjSVnBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTFwN{S3NFQh|ryPNW\lSo0zW0GQR1XS
NCI-H209MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vRcGlEPTB;MT63O|I3QSEQvF2=NVe0VXRPW0GQR1XS
EPLC-272HNFvIVlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3zjNGlEPTB;MT64OVU1QSEQvF2=M33Mb3NCVkeHUh?=
OMC-1MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUfOVW5PUUN3ME2xMlk6QDh6IN88US=>MYjTRW5ITVJ?
HCC70MnjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17pXmlEPTB;Mj6wNFgyPSEQvF2=MmHiV2FPT0WU
CAL-12TNUnnN2pOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\tSWlEPTB;Mj6wNVg3OSEQvF2=NV6wR4lyW0GQR1XS
TGBC24TKBM{nVbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\iNVdKSzVyPUKuNFI6PjFizszNMUHTRW5ITVJ?
EKVXNHfkdZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3Xd3lHUUN3ME2yMlA1QTN7IN88US=>MlziV2FPT0WU
SW1116MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfFSohKSzVyPUKuNFYxODlizszNMmDVV2FPT0WU
NCI-H2009MlrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnxTWM2OD1{LkC2NlE1KM7:TR?=NXPtXo1kW0GQR1XS
RPMI-8866MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XJV2lEPTB;Mj6wPFQ5OSEQvF2=NVm3XIx5W0GQR1XS
KARPAS-45M3PlR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rrfGlEPTB;Mj6xNlQ4QSEQvF2=MUjTRW5ITVJ?
RXF393NVXGS4R{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTJwMUOwN|Yh|ryPMYPTRW5ITVJ?
786-0NHnmT4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXfJR|UxRTJwMUi0NFYh|ryPNEH6fGZUSU6JRWK=
SCC-4MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkDoTWM2OD1{LkKxO|c3KM7:TR?=MlPrV2FPT0WU
BT-20M4LZT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWfXZlhEUUN3ME2yMlI3PzR2IN88US=>MVnTRW5ITVJ?
A498MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTJwMkm0NVUh|ryPNETsUIlUSU6JRWK=
IGROV-1M{DycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWXkbYliUUN3ME2yMlMyOjN5IN88US=>MmrXV2FPT0WU
JVM-3MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTJwM{S2OFMh|ryPNEnoW2NUSU6JRWK=
NCI-H2170NUH6Xo9DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTJwM{S3PFMh|ryPNWDPTmlLW0GQR1XS
EW-18MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI\sUZBKSzVyPUKuN|U1PzFizszNM3z2enNCVkeHUh?=
KU812NXXSTop5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTJwM{[3O|kh|ryPNYn1S2VyW0GQR1XS
NYMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI\0bldKSzVyPUKuN|czPyEQvF2=M3rXWHNCVkeHUh?=
HTC-C3NGL0R4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfHTWM2OD1{LkSyNlY4KM7:TR?=MUDTRW5ITVJ?
CFPAC-1NXPuNpk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33nNWlEPTB;Mj60N|g3PCEQvF2=MmPsV2FPT0WU
HHM{\WdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TMcmlEPTB;Mj60PVg2PCEQvF2=M4jPUHNCVkeHUh?=
MKN7MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7qXGVKSzVyPUKuOlI4PDhizszNNWnTPXhXW0GQR1XS
TE-8M1LR[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7FclBZUUN3ME2yMlY{PjV|IN88US=>MnPVV2FPT0WU
MC-IXCNFLCSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEm5VJZKSzVyPUKuOlQ1PTNizszNM4LX[HNCVkeHUh?=
DMS-79NXftXFJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTJwNkmyPFQh|ryPMXHTRW5ITVJ?
Detroit562NUP4emdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUXHRXpNUUN3ME2yMlY6QDR3IN88US=>MnLFV2FPT0WU
HuP-T4MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV:zeZk5UUN3ME2yMlczQDF6IN88US=>M2q0bnNCVkeHUh?=
QIMR-WILMlHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XNPGlEPTB;Mj63OVk2OiEQvF2=NVXQ[W4xW0GQR1XS
BB65-RCCNIKyXIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;nTWM2OD1{LkiwO|E{KM7:TR?=MoOxV2FPT0WU
PC-3MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmjOTWM2OD1{LkizN|E4KM7:TR?=NXPyZWRHW0GQR1XS
OVCAR-3Ml3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3:zeWlEPTB;Mj64OVU6PCEQvF2=NF7uXWhUSU6JRWK=
KYSE-510M3fCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFHtdpNKSzVyPUKuPFY4QDZizszNMXvTRW5ITVJ?
HC-1MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIT1R5VKSzVyPUKuPVQxOTJizszNNXTNS3VOW0GQR1XS
NCI-H1693NUPBTYRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTJwOUW4PVch|ryPNVm1dpNiW0GQR1XS
DU-4475MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{exVmlEPTB;Mj65PVA2OiEQvF2=NIT6S45USU6JRWK=
COLO-680NMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFziSYhKSzVyPUOuNFA1QTVizszNMlHSV2FPT0WU
MN-60MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2DaUmlEPTB;Mz6wOFk4PCEQvF2=NGq4dXdUSU6JRWK=
BCPAPM4PZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjmcnF3UUN3ME2zMlA5Ojl3IN88US=>NV\oR4s2W0GQR1XS
647-VM{PORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTNwMU[yNkDPxE1?MmrMV2FPT0WU
HT-1376NE[zfI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTzcmFKSzVyPUOuNlA2ODZizszNNHf4e4ZUSU6JRWK=
NCI-H1793NYXpZ3Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTNwMkGwPVgh|ryPMUDTRW5ITVJ?
SW1463MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;zTWM2OD1|LkK2NVkzKM7:TR?=MUfTRW5ITVJ?
NCI-H727NGLpU3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHzIWo5KSzVyPUOuN|g2QDRizszNM1TR[3NCVkeHUh?=
LB771-HNCM4XyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITWfYRKSzVyPUOuN|kyOjZizszNMYXTRW5ITVJ?
D-542MGM122emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYricnJwUUN3ME2zMlQ1OjJ{IN88US=>NFm0fm1USU6JRWK=
NTERA-S-cl-D1NYC4[XR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIXY[GNKSzVyPUOuOFQ6PTdizszNMX;TRW5ITVJ?
C8166MmLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTNwNE[1NlEh|ryPMYfTRW5ITVJ?
639-VNYfHRpNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfoVoxnUUN3ME2zMlU4Pzl{IN88US=>NHuzW5NUSU6JRWK=
TE-1NWjDd|BUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU\LVXpGUUN3ME2zMlU6OTZ7IN88US=>MlTmV2FPT0WU
OAW-28M1\iUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3;NO2lEPTB;Mz61PVQzPiEQvF2=NWi5fFFYW0GQR1XS
SK-LU-1NIPSXoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTNwNkC2OFUh|ryPMmjBV2FPT0WU
CaR-1NFPySJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHrROZBKSzVyPUOuOlExPDhizszNM17LbHNCVkeHUh?=
A2780MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTNwNkSwPFkh|ryPNEjybINUSU6JRWK=
C2BBe1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTNwNkS0NFch|ryPNVLPZ5VtW0GQR1XS
SK-MES-1NWfjdoRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2mxOWlEPTB;Mz62OFYyPCEQvF2=MV\TRW5ITVJ?
PANC-10-05MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTNwN{KwO|Ih|ryPMXLTRW5ITVJ?
J-RT3-T3-5NEe4fZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRTNwN{W0NFYh|ryPMnPiV2FPT0WU
ES4NFLFOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUDKR25GUUN3ME2zMlgzOjh4IN88US=>NH;vZ5VUSU6JRWK=
NCI-H28M2O3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnHVTWM2OD1|LkiyPVYyKM7:TR?=Ml3nV2FPT0WU
NCI-H1155MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIKwVHVKSzVyPUOuPFQyPTlizszNMYfTRW5ITVJ?
KURAMOCHIMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXKTmpKSzVyPUOuPFYxPTZizszNMmDmV2FPT0WU
NCI-H69NUL3XWFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTNwOUCxO|gh|ryPMn\LV2FPT0WU
IST-MES1NEnYe4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTNwOUSwNlkh|ryPMnqwV2FPT0WU
NH-12MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDST|RKSzVyPUOuPVQyQDdizszNMk\uV2FPT0WU
JVM-2NW\nXmhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml6yTWM2OD1|Lkm0O|UzKM7:TR?=NV[ze3l7W0GQR1XS
EW-16NE\0Ro5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmPSTWM2OD1|Lkm1OVc4KM7:TR?=NFLoT2xUSU6JRWK=
NCI-H441NFzqUINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFPQRWhKSzVyPUOuPVcxOTRizszNMofwV2FPT0WU
RCC10RGBM1v4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTRwMEGyOFYh|ryPMmnXV2FPT0WU
TCCSUPMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHr5TZVKSzVyPUSuNVExPSEQvF2=MXXTRW5ITVJ?
HL-60NFjoVnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVSz[ZZYUUN3ME20MlEzOjRzIN88US=>MYDTRW5ITVJ?
EW-11M4TUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\GfpRnUUN3ME20MlE{OjZzIN88US=>Ml3yV2FPT0WU
KARPAS-299NX7IS2hPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7OTWM2OD12LkOxNFE{KM7:TR?=Ml3PV2FPT0WU
SNU-C2BMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTRwM{S2PFYh|ryPNGX1PIhUSU6JRWK=
LU-139NEflW21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHJWXFKSzVyPUSuN|czPDdizszNNEHjVW5USU6JRWK=
HCC1937NXW0VFJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLBb49KSzVyPUSuN|c6QTNizszNMkfCV2FPT0WU
GR-STNGnGdI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF6xb|NKSzVyPUSuOFMyQCEQvF2=MXvTRW5ITVJ?
SK-OV-3M{nD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlP3TWM2OD12LkS2NFQzKM7:TR?=MU\TRW5ITVJ?
A172M3rNRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfm[IJkUUN3ME20MlU2PTJzIN88US=>MoLrV2FPT0WU
NB10MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYT2[5V3UUN3ME20MlU6PzhzIN88US=>NVnV[HB{W0GQR1XS
P30-OHKMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTPTWM2OD12LkixPVI6KM7:TR?=NYDpd|dOW0GQR1XS
KYSE-520M1j6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXjsVoYxUUN3ME20Mlg5ODF6IN88US=>NYq1OpJrW0GQR1XS
KNS-62NXLXfW9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3rYe2lEPTB;ND65NFgxPyEQvF2=MULTRW5ITVJ?
ES1NVH6cmlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4qyNmlEPTB;ND65OlA{PSEQvF2=MoK3V2FPT0WU
KOSC-2MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4Trd2lEPTB;ND65PVk2QSEQvF2=NFXScGJUSU6JRWK=
TE-9MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NETSdlFKSzVyPUWuNFE2OjVizszNMmCzV2FPT0WU
NCI-H1838MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\mTWM2OD13LkCyNFc3KM7:TR?=NIfnWlRUSU6JRWK=
KP-N-YNNVHlXpZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXzJR|UxRTVwMUK1PVEh|ryPNG\JbnpUSU6JRWK=
ALL-PONHXScodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTVwMkK1PFch|ryPMorsV2FPT0WU
NOMO-1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEn6cZRKSzVyPUWuNlMyPzZizszNMmrsV2FPT0WU
CGTH-W-1NWH2dIUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIHtTpZKSzVyPUWuN|g2QDRizszNMmH5V2FPT0WU
ATN-1NH\SOo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTVwNEGxPFQh|ryPNXLlfHF1W0GQR1XS
AGSNEDIUJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkC4TWM2OD13LkS5OlE5KM7:TR?=M1fNTHNCVkeHUh?=
SW13NES0WI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfXb4JrUUN3ME21MlU{OjZ3IN88US=>M2XSS3NCVkeHUh?=
SW1990MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17vXWlEPTB;NT62NlI5PSEQvF2=NEX5fppUSU6JRWK=
BFTC-905M2fPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mmr1TWM2OD13Lk[1PFc5KM7:TR?=MVvTRW5ITVJ?
RMG-IMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIn6VllKSzVyPUWuOlU6PDJizszNMofsV2FPT0WU
HD-MY-ZMmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3uz[GlEPTB;NT62PFU5OSEQvF2=NF\hO3FUSU6JRWK=
HCC1187M3\OOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTzbYRKSzVyPUWuO|ExOzJizszNNHi2b5RUSU6JRWK=
HCC2998MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUDaU2FPUUN3ME21MlcyQDd5IN88US=>M4TVT3NCVkeHUh?=
RT-112NIfjNIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTkTWM2OD13LkmwNlQ2KM7:TR?=NV\wc4Z3W0GQR1XS
CAKI-1NXm5T4tqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTZwMEC5PFUh|ryPNEHFUYZUSU6JRWK=
HDLM-2MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTZwMEG0PFkh|ryPNHXmZWRUSU6JRWK=
TE-10NE\Je4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGfEV45KSzVyPU[uNFQ5OzNizszNM{PzbXNCVkeHUh?=
KE-37M{T5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTZwMEeyOVgh|ryPM1HkTnNCVkeHUh?=
RCM-1NWHzUmJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7Ue29KSzVyPU[uNFc4OTlizszNM{P5cnNCVkeHUh?=
MewoNUXq[VFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;pZWlEPTB;Nj6xNVQ5PyEQvF2=NVvxV2ltW0GQR1XS
L-428MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHKSpRUUUN3ME22MlE5ODN5IN88US=>MmL6V2FPT0WU
8-MG-BAM4L5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmqwTWM2OD14LkG5N|c6KM7:TR?=MU\TRW5ITVJ?
SK-MEL-28NWXrXml2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXUXHE6UUN3ME22MlIxQTZ5IN88US=>M4rGVHNCVkeHUh?=
VA-ES-BJMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjiT4NKSzVyPU[uN|A1PjJizszNMX7TRW5ITVJ?
CAL-120MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTZwNEWxOlIh|ryPM4TadXNCVkeHUh?=
GAMGMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlf5TWM2OD14LkWwOlIh|ryPNVHWelJEW0GQR1XS
MSTO-221HMmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVXJR|UxRTZwNUGxO{DPxE1?NUPlS|NpW0GQR1XS
GCTM{LvZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTiUXdKSzVyPU[uOVM{QDdizszNMnziV2FPT0WU
SH-4NVzlOldzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlrUTWM2OD14LkW4PFQ1KM7:TR?=NV3JbGZyW0GQR1XS
Calu-3MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1zTTWlEPTB;Nj62OVU3QCEQvF2=MkjhV2FPT0WU
SK-HEP-1M1TIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXLrdG1XUUN3ME22MlcyPzV|IN88US=>M4PnVnNCVkeHUh?=
PFSK-1NHjrc4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfhT2pmUUN3ME22Mlc{PDd6IN88US=>NWDCU5Z3W0GQR1XS
NB12M3HrVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIr6eIRKSzVyPU[uO|g1ODRizszNM3e3R3NCVkeHUh?=
A388MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;tTWM2OD14Lki5OVIh|ryPNVTtN4FuW0GQR1XS
KLEM2\0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTZwOU[1NVYh|ryPNIK4WIFUSU6JRWK=
TE-11MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTdwMES5Olch|ryPMUfTRW5ITVJ?
NCI-H2405Mke2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zEOGlEPTB;Nz6wPFM6OyEQvF2=MonUV2FPT0WU
OVCAR-4MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlTtTWM2OD15LkG1N|Uh|ryPMmPLV2FPT0WU
KP-N-YSNV75S2RNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfscXZ7UUN3ME23MlE5OTRizszNNVjRbHZjW0GQR1XS
NOS-1M4S5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLvSlZKSzVyPUeuNlU5OjhizszNM362VXNCVkeHUh?=
DMS-114MmPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUCySpQzUUN3ME23MlI6PjNzIN88US=>NYPjdncyW0GQR1XS
NCI-H2030MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVT4bGFKUUN3ME23MlM{Pjl6IN88US=>MV3TRW5ITVJ?
HELNHG4c5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MojUTWM2OD15LkO3OVIyKM7:TR?=NETyb4xUSU6JRWK=
CAL-62MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfKWmpTUUN3ME23MlM6QDZ4IN88US=>NXvZVHgzW0GQR1XS
COLO-668MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWfxZ3RCUUN3ME23MlQ{QTZ5IN88US=>NGjGcFRUSU6JRWK=
SKG-IIIaMkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrTTWM2OD15LkS1N|gyKM7:TR?=NX7LNWpJW0GQR1XS
HCC1419NFO5XI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlvtTWM2OD15LkS2PFM{KM7:TR?=NEPuZ3NUSU6JRWK=
OS-RC-2M1;IVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3r[4QxUUN3ME23MlQ6QDl2IN88US=>NYnzZ|R2W0GQR1XS
COLO-829MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2XWT2lEPTB;Nz62OlQ3OyEQvF2=MoXPV2FPT0WU
NB13MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvNTWM2OD15LkiyOlY4KM7:TR?=NGjVUVVUSU6JRWK=
DK-MGMnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXW0Wo9kUUN3ME23Mlg{OjBzIN88US=>M3X4[nNCVkeHUh?=
SHP-77NUn0OmFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHmyTmhKSzVyPUeuPFY3PTNizszNM1LqbHNCVkeHUh?=
NCI-H661MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHfMT|BKSzVyPUiuNFU5PjdizszNNV36R2FOW0GQR1XS
AM-38NFKxR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELsWm5KSzVyPUiuNVYzQCEQvF2=MnfTV2FPT0WU
VM-CUB-1M171bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\FTWM2OD16LkG3NFI6KM7:TR?=M1m1U3NCVkeHUh?=
KYSE-70MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NELlWZpKSzVyPUiuNVk4PjFizszNM2m2NXNCVkeHUh?=
5637MkiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGnLfmlKSzVyPUiuN|ExPTVizszNMX3TRW5ITVJ?
TGBC11TKBNH\TNlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH62cVdKSzVyPUiuOFYyPjRizszNMl;tV2FPT0WU
EGI-1M37wb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;u[nZwUUN3ME24MlYxODh6IN88US=>MnHFV2FPT0WU
D-392MGNWnPWWI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDLTWM2OD16Lk[2NlE1KM7:TR?=NHLRTYhUSU6JRWK=
A673M2q0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRThwNke2NVEh|ryPNVjuNHZUW0GQR1XS
COLO-792Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XucmlEPTB;OD63OFk1PiEQvF2=MWnTRW5ITVJ?
NCI-H1792MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmLUTWM2OD16Lki4PVA{KM7:TR?=MkTyV2FPT0WU
LS-1034NE\ncWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTD[mJ2UUN3ME24Mlk1PjV{IN88US=>NXqydHltW0GQR1XS
D-566MGNYfaNlRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTlwMEG4NUDPxE1?MWTTRW5ITVJ?
NCI-H226NYXRPWpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEWxWGRKSzVyPUmuNFkh|ryPMnTnV2FPT0WU
ChaGo-K-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlnoTWM2OD17LkGwOVc6KM7:TR?=NYHEelVRW0GQR1XS
NCI-H2228NIOySY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\hW5dOUUN3ME25MlEyODhzIN88US=>NUHHSmlqW0GQR1XS
RPMI-8226MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3uxS2lEPTB;OT6xNVMxPCEQvF2=MkDtV2FPT0WU
BFTC-909M4nuW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzGSWVvUUN3ME25MlE5Ojl5IN88US=>NWWwdmRSW0GQR1XS
HPAF-IIMkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTlwMkK1NVgh|ryPNWjxZXV3W0GQR1XS
Capan-2NFju[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\vSZU2UUN3ME25MlQxOTB7IN88US=>Ml31V2FPT0WU
IA-LMNHTMUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX:2[Y1uUUN3ME25MlQyQTZ4IN88US=>MknpV2FPT0WU
KP-4MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTlwNEi4N|gh|ryPNU[xXopKW0GQR1XS
A101DM{PrPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIfnWGFKSzVyPUmuOVE4OTlizszNNV3J[lB6W0GQR1XS
EFO-21M4DvS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnzTTWM2OD17LkW4O|M2KM7:TR?=NYH4[4k4W0GQR1XS
C32MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTlwNkOzOEDPxE1?NHKzc4FUSU6JRWK=
SW837NX3MZ|h{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1G3XmlEPTB;OT64OFgzKM7:TR?=NWSxTWVKW0GQR1XS
OCI-AML2Ml3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH7SV21KSzVyPUmuPFY6PiEQvF2=NEexXVFUSU6JRWK=
NCI-H1355MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTlwOUSwPFgh|ryPMULTRW5ITVJ?
NCI-H2342NFvDdWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTFyLkCxOVUh|ryPM{TKTHNCVkeHUh?=
A204Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;sTJdKSzVyPUGwMlA1PjZizszNMkHvV2FPT0WU
CAL-51MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTFyLkC4O|ch|ryPM1HIVnNCVkeHUh?=
HCE-4MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF7Y[4VKSzVyPUGwMlEyOjJizszNMn;UV2FPT0WU
NCI-H810NUL5eWNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHG4enFKSzVyPUGwMlE2QTdizszNNFzNeItUSU6JRWK=
DJM-1M3H6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHiO2FJUUN3ME2xNE4yPzN{IN88US=>Ml3OV2FPT0WU
SK-UT-1NFjpdJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnv0TWM2OD1zMD6yOVc1KM7:TR?=MUTTRW5ITVJ?
U031M3;MSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGLvOW5KSzVyPUGwMlI3QDZizszNM2fhcnNCVkeHUh?=
YH-13MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vHd2lEPTB;MUCuN|A2PyEQvF2=NIfSTmRUSU6JRWK=
K5NHPMdm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTFyLkOzPVUh|ryPM3LnO3NCVkeHUh?=
HEC-1NWXWXJROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3pXodsUUN3ME2xNE41ODhzIN88US=>M1r5V3NCVkeHUh?=
A2058MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LudWlEPTB;MUCuOVQ6OSEQvF2=NV;ybGxuW0GQR1XS
SW962MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXDTVd3UUN3ME2xNE43OjB2IN88US=>Mke2V2FPT0WU
VMRC-RCZNU\4TFdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3S2RmlEPTB;MUCuOlc1QSEQvF2=NH31NFZUSU6JRWK=
D-336MGM{DaTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTFyLkewNFUh|ryPMl\VV2FPT0WU
LXF-289NGjqVlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnjyTWM2OD1zMD63PVY4KM7:TR?=MVXTRW5ITVJ?
SW900NG\pZ5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXJV4VKSzVyPUGwMlgzOjhizszNMm\nV2FPT0WU
K-562MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH2xTHNKSzVyPUGwMlg{QTVizszNNVW4fXF7W0GQR1XS
HCC38MnfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjtZVIxUUN3ME2xNE46PzF4IN88US=>NEnvcFBUSU6JRWK=
SF-295MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2Wz[WlEPTB;MUCuPVkxOiEQvF2=MnTUV2FPT0WU
LB831-BLCM3H5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXTVR25uUUN3ME2xNU4zPTV4IN88US=>MUTTRW5ITVJ?
FTC-133MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTFzLkOwPFEh|ryPNF\vb4FUSU6JRWK=
HCC1954MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4HDN2lEPTB;MUGuOFM3KM7:TR?=NXH5TWZSW0GQR1XS
GOTOMmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTETWM2OD1zMT61NlA3KM7:TR?=MVvTRW5ITVJ?
LS-411NNIriXo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\iZlJKSzVyPUGxMlYyODFizszNNXOxNIt3W0GQR1XS
RPMI-7951NGfoSoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XOWGlEPTB;MUGuOlM1QCEQvF2=Mn3RV2FPT0WU
NCI-H1299NUDkNIpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4XBPGlEPTB;MUGuOlY1PyEQvF2=Mn:1V2FPT0WU
MLMAMkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTFzLk[5PVch|ryPNWPoPHBxW0GQR1XS
MMAC-SFMlToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33QdGlEPTB;MUGuO|I2OiEQvF2=MVHTRW5ITVJ?
UM-UC-3MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37ocGlEPTB;MUGuO|QzOSEQvF2=NF7sXmNUSU6JRWK=
SCC-9MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLOTWM2OD1zMT64NVUyKM7:TR?=M{DJeXNCVkeHUh?=
HOSM1\VNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFPON2hKSzVyPUGxMlg3QDNizszNMn3LV2FPT0WU
OE19NUTLS|VUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVHXWplDUUN3ME2xNU46OzZ5IN88US=>NEXvcY1USU6JRWK=
Mo-TMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfLT2xpUUN3ME2xNU46PTRzIN88US=>NY\pTI9zW0GQR1XS
CAMA-1MoXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDZTWM2OD1zMj6xOlM{KM7:TR?=NUfjd45LW0GQR1XS
U-118-MGM3PPdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4nPT2lEPTB;MUKuNlQ1OSEQvF2=NG\zN29USU6JRWK=
KS-1M2LCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXrJR|UxRTF{LkK4N|Ih|ryPM1uzcnNCVkeHUh?=
JARM2nFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2O3b2lEPTB;MUKuN|M3QSEQvF2=Mlv0V2FPT0WU
ABC-1NEG0RW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7rV2hGUUN3ME2xNk4{PDFizszNNVj6WXdvW0GQR1XS
DaoyMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MofRTWM2OD1zMj60OVQzKM7:TR?=M1y4fnNCVkeHUh?=
C3AM{Sz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTF{LkW3PFUh|ryPM1PGcHNCVkeHUh?=
GT3TKBMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1uyUWlEPTB;MUKuOlMzPyEQvF2=M{KyOHNCVkeHUh?=
DMS-273MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTF{Lki2N|Mh|ryPMlHwV2FPT0WU
G-361M4fiT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;lTWM2OD1zMj65NVI6KM7:TR?=MX\TRW5ITVJ?
RH-18MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEftRZFKSzVyPUGzMlI6PjJizszNMWnTRW5ITVJ?
SN12CNYLYZ4hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnKwTWM2OD1zMz6zPFA5KM7:TR?=NYXqOHVZW0GQR1XS
NCI-H1993NHrNN2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4LNOWlEPTB;MUOuOFI5PSEQvF2=MWLTRW5ITVJ?
LOXIMVINI[5SW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nnTWlEPTB;MUOuOlE2OSEQvF2=NUDHR3BQW0GQR1XS
SK-PN-DWNIP0UZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlO4TWM2OD1zMz64OFI4KM7:TR?=MVjTRW5ITVJ?
KALS-1MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk[3TWM2OD1zMz64OVI2KM7:TR?=NXXvS3l3W0GQR1XS
LAN-6M13Tc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGT3NHFKSzVyPUG0MlI2OyEQvF2=MWrTRW5ITVJ?
A549MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnrFTWM2OD1zND60O|EzKM7:TR?=MWjTRW5ITVJ?
RDM3q3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXjJR|UxRTF2LkS4NVMh|ryPNG\DVVVUSU6JRWK=
TGBC1TKBNWnmeFNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MonNTWM2OD1zND62OlE2KM7:TR?=NV\lUpY2W0GQR1XS
NCI-H630Mn:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnXiTWM2OD1zND65OFY4KM7:TR?=MnX5V2FPT0WU
MIA-PaCa-2NGPoNoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTF2Lkm2PUDPxE1?MlrzV2FPT0WU
NCI-H1755MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTF2Lkm5OVMh|ryPNVT5c3F4W0GQR1XS
MOLT-4NIPtRmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWrJR|UxRTF3LkC0PVch|ryPNYDMXlVnW0GQR1XS
CW-2MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M36zRmlEPTB;MUWuNVQzOSEQvF2=MkjNV2FPT0WU
COLO-320-HSRMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTF3LkWzNFch|ryPMmDHV2FPT0WU
UMC-11MlfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nZeGlEPTB;MUWuO|UzOyEQvF2=MojqV2FPT0WU
MCF7MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{nEU2lEPTB;MUWuPFE1PSEQvF2=NUP4dVFoW0GQR1XS
NCI-H23MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTF3Lki0N|gh|ryPM3rQO3NCVkeHUh?=
HuCCT1Mkn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRTF3Lki3OEDPxE1?NXT1VZRJW0GQR1XS
MPP-89NGjoclNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTF3Lkm0NVch|ryPNXLxS|U{W0GQR1XS
HT55NXy5T5kyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH63cmZKSzVyPUG1Mlk1PzhizszNNUnlV|k4W0GQR1XS
no-11Mn7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPrT3BWUUN3ME2xOU46PjZ|IN88US=>M17EbXNCVkeHUh?=
GP5dNUi5ZoF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPDTWM2OD1zNj6yNVg4KM7:TR?=Ml25V2FPT0WU
BHT-101NYTZclFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIn4dVVKSzVyPUG2MlI1OzlizszNM3zHdXNCVkeHUh?=
M059JMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmP3TWM2OD1zNj6yPFQh|ryPMmrrV2FPT0WU
D-283MEDM2Da[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDpTWM2OD1zNj60NlA6KM7:TR?=NYr4RnpCW0GQR1XS
BENNX;VdW5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjUUZExUUN3ME2xOk42OTV3IN88US=>NFHBOZZUSU6JRWK=
LB373-MEL-DMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{HudGlEPTB;MU[uO|I{OiEQvF2=NEfocnBUSU6JRWK=
MEL-HOMlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIX5NWxKSzVyPUG2Mlg5PTRizszNMlzlV2FPT0WU
GI-ME-NM{OxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfmTWM2OD1zNj65NFMzKM7:TR?=MUXTRW5ITVJ?
RKONGTaR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4LNWGlEPTB;MUeuNFc1QCEQvF2=NIq0eHFUSU6JRWK=
MZ2-MELM1GzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1rlW2lEPTB;MUeuNVM{KM7:TR?=M3WzfnNCVkeHUh?=
NCI-H1573MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\CZpFtUUN3ME2xO{4zQDJ4IN88US=>MVrTRW5ITVJ?
NCI-H1581NGXLT2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XZZmlEPTB;MUeuOFQyOSEQvF2=MUXTRW5ITVJ?
NCI-H747M4D1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTF5LkWyPVch|ryPM3fmTnNCVkeHUh?=
SW1783Mki1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHHp[5RKSzVyPUG3MlY1OTVizszNM{S5eHNCVkeHUh?=
Calu-6M3fGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDkU5JLUUN3ME2xO{43Pzh{IN88US=>NFPWd5JUSU6JRWK=
SF268MoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTF5Lk[5Olkh|ryPNFGyS|RUSU6JRWK=
ES8MmTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4eyfmlEPTB;MUeuPFU6OyEQvF2=NGjRXGJUSU6JRWK=
KM-H2MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTuTWM2OD1zNz65OFEyKM7:TR?=NXHUepVVW0GQR1XS
D-502MGNYDFTYp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXYdGxIUUN3ME2xO{46QDB6IN88US=>NWfQNVVWW0GQR1XS
HLEMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWHpcFZxUUN3ME2xPE4{OTR6IN88US=>NYjnb5FlW0GQR1XS
SW982M4P1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37RPWlEPTB;MUiuOFA4PSEQvF2=NF[2TJpUSU6JRWK=
MDA-MB-361MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\XSGlEPTB;MUiuOVU5QCEQvF2=MmPHV2FPT0WU
NCI-H1563M{PQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnqTWM2OD1zOD63NVI1KM7:TR?=MUPTRW5ITVJ?
MFE-280NFLk[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEHOXplKSzVyPUG4MlczQTNizszNNWraWGNCW0GQR1XS
U251MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlHsTWM2OD1zOD63N|Q4KM7:TR?=NVPWVWlzW0GQR1XS
KNS-42MoPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\zTWM2OD1zOD64NFE2KM7:TR?=MWXTRW5ITVJ?
U-266NXvaU2NTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTF6Lki2OFkh|ryPNETCW2RUSU6JRWK=
OVCAR-8NUHNTJZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEewfIVKSzVyPUG4MlkzPzZizszNNV7NXo9YW0GQR1XS
MFH-inoNHXOVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIf4cpdKSzVyPUG4Mlk3PjlizszNMXzTRW5ITVJ?
D-263MGNF\IW4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnLJTWM2OD1zOT6wNVczKM7:TR?=MVnTRW5ITVJ?
NCI-H1437MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRTF7LkC0Olch|ryPNF21UmZUSU6JRWK=
NCI-H1048NIewepRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTwTWM2OD1zOT6yN|I3KM7:TR?=NXnvfVBFW0GQR1XS
NCI-H446MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTF7LkO1PFkh|ryPMlLwV2FPT0WU
NCI-N87MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGK4VVZKSzVyPUG5MlU6QTJizszNNU\zdXJJW0GQR1XS
WM-115NIjzUHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXRTWM2OD1zOT62O|c1KM7:TR?=MV\TRW5ITVJ?
HuH-7NVXQdlZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;pTWM2OD1zOT63OFIyKM7:TR?=MX7TRW5ITVJ?
NCI-H650NYHMSlJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHv3Ro1KSzVyPUG5Mlc2ODhizszNNGXNb3NUSU6JRWK=
TYK-nuMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnX3TWM2OD1zOT64N|c5KM7:TR?=MXXTRW5ITVJ?
BeckerM3nq[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPPPXkyUUN3ME2xPU45PTR5IN88US=>MkG1V2FPT0WU
BB49-HNCM{DoT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\WR5NKSzVyPUG5MlkzKM7:TR?=MkiwV2FPT0WU
HGC-27MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFzr[nBKSzVyPUKwMlE{QTRizszNMVXTRW5ITVJ?
SiHaMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU\zSXZtUUN3ME2yNE4{PzF{IN88US=>Ml\6V2FPT0WU
LB2518-MELNEC0cpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTJyLkO3N|kh|ryPMmntV2FPT0WU
TE-5MoKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWDkdpU6UUN3ME2yNE44PDh{IN88US=>MYXTRW5ITVJ?
IST-SL1MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnvXTWM2OD1{MD63PFc6KM7:TR?=NXHacYpTW0GQR1XS
A375MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFvIdoZKSzVyPUKxMlA2PjdizszNNWLGSItlW0GQR1XS
MC116MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTJzLkC3NlMh|ryPNGHxS2ZUSU6JRWK=
GI-1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmPoTWM2OD1{MT6xO{DPxE1?MoK4V2FPT0WU
HOP-62MmDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWG5UIs{UUN3ME2yNU4zPzh2IN88US=>MYfTRW5ITVJ?
PA-1NH7qXoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fMfmlEPTB;MkGuNlc5PyEQvF2=MmT2V2FPT0WU
HTNWHkW4VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIK4S4lKSzVyPUKxMlQ{OzFizszNMYDTRW5ITVJ?
HUTU-80MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7VT|NUUUN3ME2yNU41OzN4IN88US=>MoTRV2FPT0WU
NCI-H1975NVrt[JBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTJzLkS2NUDPxE1?NX3JfIozW0GQR1XS
GAKMlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTJzLkS5PUDPxE1?NFz4UpFUSU6JRWK=
SK-N-ASNIn0[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX[3PI1bUUN3ME2yNU42PjF7IN88US=>M2HQW3NCVkeHUh?=
OE33Ml3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\zUGlEPTB;MkGuOlA1PiEQvF2=MoT1V2FPT0WU
YKG-1NYfIe2I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULBTnNnUUN3ME2yNU43PTR3IN88US=>NHzQOlFUSU6JRWK=
CAL-85NFm3XoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTJzLkmzNFUh|ryPNXW1VJE5W0GQR1XS
NCI-H2347NGG0dIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1n4VWlEPTB;MkGuPVQzQCEQvF2=NGX2d5FUSU6JRWK=
PANC-08-13NEW5NlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTJ{LkCxNVkh|ryPNFXBeGpUSU6JRWK=
SK-N-FIM3SxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTJ{LkOwO|Qh|ryPM3TW[3NCVkeHUh?=
NEC8NIL6PGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHUcY1lUUN3ME2yNk42ODd6IN88US=>MlLyV2FPT0WU
AN3-CAMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTJ{Lk[wPFQh|ryPMXjTRW5ITVJ?
HuO9MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFX5[5VKSzVyPUKyMlc{QTZizszNMVnTRW5ITVJ?
COLO-800M4HEdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTJ{Lke2OVMh|ryPMnLwV2FPT0WU
HT-29MmT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3rac2lEPTB;MkKuPFgzOyEQvF2=NIjWc5dUSU6JRWK=
OC-314NYqzS2RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;QTWM2OD1{Mj64PFQ2KM7:TR?=NGDIcmZUSU6JRWK=
G-401MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1\qfGlEPTB;MkOuNFQ3OiEQvF2=NUPNbnpLW0GQR1XS
Saos-2M3vMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2C2dGlEPTB;MkOuOVE5OiEQvF2=NFS2bnhUSU6JRWK=
UACC-62M3PBWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYPJR|UxRTJ|LkW4N|Mh|ryPMWHTRW5ITVJ?
D-247MGMkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlfnTWM2OD1{Mz63PVM6KM7:TR?=NFzB[nBUSU6JRWK=
COLO-741Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPOdW9KSzVyPUKzMlk2PjVizszNMkDOV2FPT0WU
ES3M4Lwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXf5eGJjUUN3ME2yOE4xODJ|IN88US=>MleyV2FPT0WU
LNCaP-Clone-FGCNVrJU21NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTJ2LkCyNVEh|ryPMkjHV2FPT0WU
SW1710NVLwb5VGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTJ2LkG1NFYh|ryPM37xdXNCVkeHUh?=
LU-99ANEfNeFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTJ2LkG4OFEh|ryPM{\WNXNCVkeHUh?=
HOP-92MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGnnUZJKSzVyPUK0MlczPSEQvF2=MVXTRW5ITVJ?
LS-123MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;0e5FxUUN3ME2yOE46PjF2IN88US=>NU\UNppYW0GQR1XS
T84NXW3ZYpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2G1dmlEPTB;MkSuPVc3PSEQvF2=MYrTRW5ITVJ?
HCT-116MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVW5eGRlUUN3ME2yOU41OTh4IN88US=>NETXXI1USU6JRWK=
M14M1LSbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3yTWM2OD1{NT60OFQ4KM7:TR?=MoOyV2FPT0WU
OCUB-MNHrlOWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3NTWM2OD1{NT60OFU3KM7:TR?=MUPTRW5ITVJ?
MKN45NV7jXolbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFrjW2hKSzVyPUK1MlY{OTVizszNMYDTRW5ITVJ?
LCLC-97TM1M2mxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nMRmlEPTB;MkWuO|I5PSEQvF2=MWTTRW5ITVJ?
RVH-421M4PFZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37lUmlEPTB;MkWuPFE3OSEQvF2=NVHv[HM6W0GQR1XS
NKS-81-FDM4nyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mkm4TWM2OD1{NT65NFIyKM7:TR?=M1vkbnNCVkeHUh?=
NCI-H596MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTJ4LkC0PFch|ryPMVnTRW5ITVJ?
GB-1M3\XeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vUcGlEPTB;Mk[uNVg4QSEQvF2=MYnTRW5ITVJ?
ZR-75-30MnK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{fRW2lEPTB;Mk[uNlI6PyEQvF2=MWfTRW5ITVJ?
U-2-OSNV\xRVNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHWPFl3UUN3ME2yOk4{PzV5IN88US=>M1TUcnNCVkeHUh?=
HuP-T3MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PYV2lEPTB;Mk[uOlExOiEQvF2=NGnJe29USU6JRWK=
MOLT-16NXq2[HZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFe5T|hKSzVyPUK2MlYyPjZizszNM3r5N3NCVkeHUh?=
U-87-MGMmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlu2TWM2OD1{Nj63OFM5KM7:TR?=M{nIdXNCVkeHUh?=
8505CMkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFTWSIdKSzVyPUK2MlkyOjZizszNMl:0V2FPT0WU
SK-MEL-3MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjzdphbUUN3ME2yOk46QDJ6IN88US=>NEHx[4pUSU6JRWK=
COLO-824M3;ESGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;aUnhDUUN3ME2yO{4zOTl3IN88US=>MWfTRW5ITVJ?
EW-1NHrUNJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\pV2lEPTB;MkeuN|U2PCEQvF2=M3TyU3NCVkeHUh?=
UACC-257M3ns[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7MRVFKSzVyPUK3MlM5ODRizszNNYPMbIJtW0GQR1XS
Hs-578-TMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTJ5LkWyPVkh|ryPMmrKV2FPT0WU
UACC-893NX\lV5NzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn31TWM2OD1{Nz62OlMyKM7:TR?=MWTTRW5ITVJ?
MHH-NB-11M1WwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrsTWM2OD1{Nz64NFA4KM7:TR?=NUPsWo8xW0GQR1XS
KYSE-410NHvQUJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorvTWM2OD1{OD6yO|c6KM7:TR?=NX;BXmQxW0GQR1XS
SF126MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTJ6Lke0N|Uh|ryPNWjrSpE4W0GQR1XS
HT-144NInzWZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWrJR|UxRTJ7LkOzOlIh|ryPNUPXV25SW0GQR1XS
SW1573MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlO5TWM2OD1{OT6zOVA6KM7:TR?=NXXJWXFzW0GQR1XS
SW620NI\D[ndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnLhTWM2OD1{OT6zOlQyKM7:TR?=NEHxOGRUSU6JRWK=
SCHM4XYO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXCfG5KSzVyPUK5Mlg5OzFizszNMlLkV2FPT0WU
EW-22MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfqXoRKSzVyPUOwMlE6PjlizszNNGPVbZFUSU6JRWK=
H4M2XVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NETRPFlKSzVyPUOwMlQ3PTRizszNNHHXV|hUSU6JRWK=
CAS-1MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2H5S2lEPTB;M{CuO|g2QSEQvF2=NHTp[HZUSU6JRWK=
MG-63MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHKxXY9KSzVyPUOwMlg1PzhizszNMmjiV2FPT0WU
MDA-MB-415MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3LTdGlEPTB;M{GuNVc2OyEQvF2=M1nZfHNCVkeHUh?=
NCI-H1395NWDxe5VJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2ey[mlEPTB;M{GuNlMzQCEQvF2=NYLVVIZpW0GQR1XS
Ca-SkiNVezTIRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTheIlVUUN3ME2zNU4{OTd5IN88US=>NXOzcox5W0GQR1XS
BxPC-3MkfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nVXWlEPTB;M{GuN|czQSEQvF2=NG\QU3BUSU6JRWK=
A3-KAWMofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\ZUGlEPTB;M{GuOFQ4OSEQvF2=M{jTc3NCVkeHUh?=
T-24M{LjTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2XRS2lEPTB;M{GuO|M3OiEQvF2=NVP3UWdLW0GQR1XS
NCI-H2029NGDsPGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRTNzLke3OlUh|ryPMUnTRW5ITVJ?
YAPCMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjiUnhKSzVyPUOyMlA1ODdizszNMlOxV2FPT0WU
SK-MEL-2M4j5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTN{LkC1NkDPxE1?M3n5[3NCVkeHUh?=
LS-513NI\OUlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVHIRYxEUUN3ME2zNk4yOTh5IN88US=>Mn[yV2FPT0WU
AsPC-1NIT2XJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MknFTWM2OD1|Mj6zOlA2KM7:TR?=MoLtV2FPT0WU
KYSE-150NX;Y[GpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYnqVWw4UUN3ME2zNk4{Pzd|IN88US=>MWXTRW5ITVJ?
NCI-H520M{XyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nNXGlEPTB;M{KuOFQ5OiEQvF2=MWPTRW5ITVJ?
JEG-3NVfFTVZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PoZWlEPTB;M{OuNFk4OSEQvF2=NY\MeGc{W0GQR1XS
GMS-10M{DDPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPkTWM2OD1|Mz6zNFA1KM7:TR?=NIrOXHZUSU6JRWK=
HT-1080M{Gyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{WwemlEPTB;M{OuN|kh|ryPNEL2VnZUSU6JRWK=
NCI-H1651MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUH6N2NoUUN3ME2zN{4{QTZizszNM2XZSHNCVkeHUh?=
NCI-H2122NWrxS49lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\FO3JKSzVyPUOzMlU2PzRizszNMWfTRW5ITVJ?
ES5NWHjdHdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{nQPGlEPTB;M{OuO|I6OiEQvF2=MVTTRW5ITVJ?
8305CNEXQNWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWj2RWE2UUN3ME2zN{46QTN5IN88US=>MWLTRW5ITVJ?
KM12NFH2VZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmPITWM2OD1|ND6wOFc5KM7:TR?=MV\TRW5ITVJ?
HCT-15NVzWT|BnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3fjSmlEPTB;M{SuNVI4KM7:TR?=NF\2e5BUSU6JRWK=
OVCAR-5NUDyPYtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTN2LkKxPFIh|ryPM3nXenNCVkeHUh?=
NCI-H2291NWTD[5hUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;Eb|ZVUUN3ME2zOE4zPDd{IN88US=>MnfCV2FPT0WU
CP50-MEL-BMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrr[29JUUN3ME2zOE43PTl{IN88US=>NGi4ZpFUSU6JRWK=
C-33-AMkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIj6VHdKSzVyPUO0MlY5PTdizszNMmntV2FPT0WU
NCI-H2452NYLwfWFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4S4XWlEPTB;M{SuO|g5OiEQvF2=NIjrRYNUSU6JRWK=
MDA-MB-157NU\qS4hlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlTMTWM2OD1|ND64NVk{KM7:TR?=M3;q[nNCVkeHUh?=
LN-405MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTN3LkSzNFgh|ryPM2rkSHNCVkeHUh?=
MDA-MB-231M2D3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIT3dFRKSzVyPUO1MlUxPTRizszNMmTrV2FPT0WU
EW-24NUK1PXpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLVTWM2OD1|NT62N|M2KM7:TR?=M2HtdHNCVkeHUh?=
MKN28MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTBdI83UUN3ME2zOU45OjN4IN88US=>Ml;yV2FPT0WU
KINGS-1NGjGSFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHqTWM2OD1|NT64OFM1KM7:TR?=NX\OT2pYW0GQR1XS
LC-2-adNYjRfXI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVnhNJZvUUN3ME2zOk43QTlizszNM37qNXNCVkeHUh?=
IGR-1NETnZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vZWGlEPTB;M{[uO|A4PSEQvF2=M2Hvb3NCVkeHUh?=
SW626MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnW1TWM2OD1|Nz6wOFE4KM7:TR?=NUjYTZoxW0GQR1XS
ONS-76MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWfic2l1UUN3ME2zO{4yOzB7IN88US=>M4XpT3NCVkeHUh?=
T98GM1fSS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknkTWM2OD1|Nz64OlM2KM7:TR?=M3zpNHNCVkeHUh?=
NB14MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkLxTWM2OD1|OD60OVQ1KM7:TR?=NGj1XVlUSU6JRWK=
D-423MGNIjsOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmLJTWM2OD1|OD60PFY6KM7:TR?=NVrJfpZMW0GQR1XS
NCI-H510AMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTN6Lk[0OVEh|ryPMVPTRW5ITVJ?
NMC-G1NV7BS5ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3Qe4NXUUN3ME2zPE44OjJ{IN88US=>MlzTV2FPT0WU
SW948NYPDV41WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTN6Lki5OFkh|ryPNVHne41CW0GQR1XS
MFM-223MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTN6Lkm0N|Eh|ryPNH\JfZFUSU6JRWK=
PAN1NGGxUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUmyfFNuUUN3ME2zPE46QTF7IN88US=>MoX3V2FPT0WU
MZ7-melM{jl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTxTWM2OD1|OT6xNVk6KM7:TR?=MUPTRW5ITVJ?
COLO-679NE[1cZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nZZ2lEPTB;M{muPVcxQCEQvF2=NGXt[YJUSU6JRWK=
SW872NIjrUVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1Pze2lEPTB;NECuNlA{OSEQvF2=MUfTRW5ITVJ?
HT-1197MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH[2WolKSzVyPUSwMlI5PjlizszNMVzTRW5ITVJ?
ES6MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXUTWM2OD12MD60OVUzKM7:TR?=M2D3UHNCVkeHUh?=
SNU-387MmLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fLdWlEPTB;NECuPFI{QCEQvF2=MoHjV2FPT0WU
T47DMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;NTWM2OD12MT6wNVkzKM7:TR?=M{X0dHNCVkeHUh?=
G-402MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXaTWM2OD12MT6wPFA6KM7:TR?=MYXTRW5ITVJ?
MZ1-PCNGjMbWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\ye|dKSzVyPUSxMlgyKM7:TR?=Mlv3V2FPT0WU
SW1417MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEm3[4RKSzVyPUSyMlMxOyEQvF2=M2\EZXNCVkeHUh?=
RERF-LC-MSMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDSOVlKSzVyPUSyMlUxQDdizszNNGHk[3RUSU6JRWK=
SF539NYP5V4dST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTR{LkW1Nlkh|ryPNGLNZ5pUSU6JRWK=
ESS-1MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVj1NIRmUUN3ME20N{42PTV6IN88US=>MYDTRW5ITVJ?
RO82-W-1Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2SwOWlEPTB;NEOuOlE2OyEQvF2=NWTrN253W0GQR1XS
S-117NYXpO5UxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkHtTWM2OD12Mz62PVU5KM7:TR?=NGrZWYRUSU6JRWK=
SW756M3TrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTR|LkiyOFIh|ryPMWnTRW5ITVJ?
CP66-MELMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTR3LkexOFMh|ryPMnvtV2FPT0WU
H-EMC-SSNXL0bJE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\PR|FKSzVyPUS1Mlc3QTNizszNM3zTVXNCVkeHUh?=
NCI-H2052MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\TTWM2OD12NT65NFI4KM7:TR?=NVLET2RSW0GQR1XS
SW684MojOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXnGT|N7UUN3ME20O{4xODhzIN88US=>M{Tj[nNCVkeHUh?=
HCC1569NGmxT2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFzJZ2lKSzVyPUS3MlE3PThizszNNY\0NW9CW0GQR1XS
KGNM2rLSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlv0TWM2OD12Nz6zN|EyKM7:TR?=NUjZcWt1W0GQR1XS
LCLC-103HNUjjbZdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTR5LkS0NFQh|ryPMl:4V2FPT0WU
SW780M1TYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFj1fYRKSzVyPUS3MlY{PTFizszNNGPmbZFUSU6JRWK=
NCI-H1703M4TVe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTR6LkOzOVIh|ryPNWX1bGF5W0GQR1XS
HCC1395MoroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjUT4N3UUN3ME20PE44PDN{IN88US=>MkD3V2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Gefitinib (100 mg/kg) improves the anti-tumor effect of radiotherapy in LoVo tumor xenografts. [3] Gefitinib treatment of nude mice bearing established human GEO colon cancer xenografts reveals a reversible dose-dependent inhibition of tumor growth because GEO tumors resumes the growth rate of controls at the end of the treatment. [4]
Features A potent EGFR tyrosine kinase inhibitor.

Protocol(Only for Reference)

Cell Assay: [1]

Cell lines NR6, NR6M and NR6W cells
Concentrations 0-2 μM
Incubation Time 72 hours
Method Exponentially growing cells including NR6, NR6M, NR6M and NR6W cells are seeded in sextuple in 96-well plates at a concentration of 2000 cells/well, allowed to adhere and subsequently washed in PBS and incubated overnight in medium containing 0.5% FCS. Cells are then treated with varying concentrations (0-2 μM) of Gefitinib or the solute control DMSO and EGF. The optimal EGF concentration for inducing proliferation of NR6wtEGFR and NR6W cells has previously been determined and hence NR6wtEGFR and NR6W cells are supplemented with 10 nM and 0.1 nM EGF, respectively. EGF is not added to NR6 and NR6M cells. After 72 hours the amount of cells are measured by performing a MTT proliferation assay.

Animal Study: [3]

Animal Models Female nude mice (cba nu/nu) aged 8–10 weeks are intra-dermal injected with LoVo cells.
Formulation 0.5% polysorbate
Dosages 100 mg/kg
Administration Once daily by oral administration (0.1 mL/10 g body weight) for 14 days

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Pedersen MW, et al. Br J Cancer. 2005, 93(8), 915-923.

[2] Moasser MM, et al. Cancer Res. 2001, 61(19), 7184-7188.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-23)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02824458 Recruiting EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors Sun Yat-sen University June 2016 Phase 3
NCT02740894 Completed Is Targeted Therapy Increasing Survival Inoperable Nonsmall Cell Lung Cancer With Spinal Metastasis ? Taipei Veterans General Hospital, Taiwan February 2016 --
NCT02347839 Recruiting Lung Cancer Sun Yat-sen University January 2016 Phase 2
NCT02588261 Recruiting Non-small Cell Lung Cancer (NSCLC) Astellas Pharma Global Development, Inc.|Astellas Pharma Inc November 2015 Phase 3
NCT02326285 Recruiting Non-squamous Non-small Cell Lung Cancer Stage II|Non-squamous Non-small Cell Lung Cancer Stage IIIA|Non-squamous Non-small Cell Lung Cancer Stage I  ...more Non-squamous Non-small Cell Lung Cancer Stage II|Non-squamous Non-small Cell Lung Cancer Stage IIIA|Non-squamous Non-small Cell Lung Cancer Stage IIIB|Activating EGFR Mutation|NSCLC AIO-Studien-gGmbH|AstraZeneca November 2015 Phase 2|Phase 3

view more

Chemical Information

Download Gefitinib (ZD1839) SDF
Molecular Weight (MW) 446.90
Formula

C22H24ClFN4O3

CAS No. 184475-35-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 89 mg/mL (199.14 mM)
Ethanol 4 mg/mL (8.95 mM)
Water <1 mg/mL (<1 mM)
In vivo 5% DMSO+corn oil 2.5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine

Customer Product Validation(11)


Click to enlarge
Rating
Source Mol Syst Biol 2011 7, 486. Gefitinib (ZD1839) purchased from Selleck
Method qPCR analysis
Cell Lines glioblastoma cell lines
Concentrations 5 μM, 50 ng/ml
Incubation Time 6 h
Results We perturbed the activity of the EGFR by activating it using one of its ligands (EGF) and inhibiting it with a selective EGFR inhibitor (Gefitinib). As readout, we measured the transcriptional effect on SOCS2 (a modulator of STAT signaling), NR2E1(also known as TLX , a transcription factor believed to be important for neural stem cell renewal), yielding results compatible with a coupling between hub perturbation and transcriptional response.

Click to enlarge
Rating
Source Oncogene 2010 30, 737-750. Gefitinib (ZD1839) purchased from Selleck
Method Western blot
Cell Lines MEFs
Concentrations 1 μM
Incubation Time 48 h
Results We found that gefitinib, a specific EGFR inhibitor, almost completely recapitulated the results obtained by genistein (Figure a). Consistent with these results, we observed increased EGFR phosphorylation within 2 days of RECK depletion , with insignificant change in its protein amount (Figure b).

Click to enlarge
Rating
Source Carcinogenesis 2010 31, 1948–1955 . Gefitinib (ZD1839) purchased from Selleck
Method Luciferase assay
Cell Lines LNCaP-AI cells, LNCaP cells
Concentrations 20 μM
Incubation Time 24 h
Results EGF significantly stimulates the promoter activity of sPLA2-IIa gene in both LNCaP and LNCaP-AI cells (shown in LNCaP-AI cells), whereas Gefitinib and other inhibitors all tested downregulated the promoter activity both at the basal level (shown in LNCaP cells) and in response to EGF stimulation (shown in LNCaP-AI cells)

Click to enlarge
Rating
Source Carcinogenesis 2010 31, 1948–1955. Gefitinib (ZD1839) purchased from Selleck
Method ELISA
Cell Lines LNCaP-AI cells
Concentrations 20 μM
Incubation Time 24 h
Results Lapatinib, LY294002 and Bortezomib significantly inhibited sPLA2-IIa secretion, whereas Erlotinib, Gefitinib and CI-1033 had a moderate effect in LNCaP-AI cells .

Click to enlarge
Rating
Source J Immunother 2011 34(4), 372-81. Gefitinib (ZD1839) purchased from Selleck
Method Cytotoxicity assay
Cell Lines NK-92 cells/ lung cancer cells
Concentrations 10 μM
Incubation Time 24 h
Results Susceptibility of lung cancer cells to cytolytic activity of NK cells was significantly increased by treatment with EGFR inhibitors (erlotinib/gefitinib) and was reversed by blocking step using mAb against NKG2D before the assay in all lung cancer cells.

Click to enlarge
Rating
Source Antiviral Res 2010 89, 64-70. Gefitinib (ZD1839) purchased from Selleck
Method Proliferation assay, Plaque reduction test, Western blot, Real-time PCR
Cell Lines Hep2 cells
Concentrations 0.01-1000 μM
Incubation Time
Results While for Gefitinib concentrations between 100 μM and 0.01 μM the proliferation rate was almost 100% of the controls, only at concentrations of 1000 μM a slight (24%) decline in proliferation was observed (Fig.A). IC50 values of Gefitinib for plaque size reduction were calculated by dividing plaque size by total size of one tissue culture plate well for each compound concentration. A non-linear regression fit curve analysis from the calculated values revealed for plaque size reduction an IC50 value of 4.93μM for Gefitinib(Fig. B).The analysis of phosphorylated EGFR and of the downstream signaling kinases ERK1/2 in cell lysates of the assay confirmed the dose dependency of the antiviral effect of Gefitinib. Kinase activ-ities were completely suppressed at concentrations above 1μM as determined by Western blot analysis. VACV proteins were not detectable between 10 μM and 100 μM in Western blot analysis anymore (Fig. C).

Click to enlarge
Rating
Source Antiviral Res 2010 89, 64-70. Gefitinib (ZD1839) purchased from Selleck
Method Immunofluorescence
Cell Lines Hep2 cells
Concentrations 0.01-1000 nM
Incubation Time 96 h
Results As shown in Fig. A, an immunofluorescent staining of a plaque reduction test was performed 96 h after viral infection. VACV infected cells were treated with 1000 μM, 1 μM or 0.01 μM Gefitinib and compared to uninfected cells after 96 h incubation. At concentrations of 1000 μM Gefitinib virus induced plaques were rarely found in cell culture and infected cells only could be identified by fluorescent staining of orthopoxvirus proteins (green) but not by light microscopy. At this Gefitinib concentration EGFR phosphorylation was completely suppressed in the cells and even the uninfected, untreated control cells show a stronger pEGFR signal (control, red). Occasionally found plaques, visible by flourescence microscopy only, showed a very compact shape with minimal disruption in its center. At the lower Gefitinib concentrations plaques showed an increasing number of infected and pEGFR positive cells (merge, yellow) and a surround-ing small zone of solely pEGFR positive cells (red). The lower the Gefitinib concentration the more plaques with a disrupted center were observed (1μM and 0.01μM). Most of the cells localized in the center of the plaque were positive for orthopoxvirus infection but negative for pEGFR ( Fig. B).

Click to enlarge
Rating
Source Mol Biosyst 2011 7, 3223-33. Gefitinib (ZD1839) purchased from Selleck
Method Immunoprecipitation/Western blotting
Cell Lines
Concentrations 5 μM
Incubation Time 0-1 h
Results In the presence of the EGFR tyrosine kinase inhibitor Z D1839 (Iressa) revealed that the observed increase in binding between PCM1 and Azi1 is specific to EGFs timulation and requires E GFR activation.

Click to enlarge
Rating
Source Int J Proteomics 2011 215496. Gefitinib (ZD1839) purchased from Selleck
Method CEER assay
Cell Lines H358 cell line
Concentrations 0.01-10 μM
Incubation Time 4 h
Results HER1 and/or HER2 pathway-activated cell lines, H358 , had their activation blocked by the HER1/2 kinase inhibitors Gefitinib.

Click to enlarge
Rating
Source 2010 Dr. Zhang of Tianjin Medical University. Gefitinib (ZD1839) purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-5 nM
Incubation Time 24 h
Results

Click to enlarge
Rating
Source 2010 Dr. Vicky Tin from University of Hong Kong. Gefitinib (ZD1839) purchased from Selleck
Method MTT assay
Cell Lines H1299 cells, H358 cells, H25 cells, HCC827 cells
Concentrations 0-400 nM
Incubation Time 72 h
Results

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related EGFR Products

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Afatinib (BIBW2992) Dimaleate

    Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

  • Poziotinib (HM781-36B)

    Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.

  • Erlotinib HCl (OSI-744)

    Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Afatinib (BIBW2992)

    Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

  • Osimertinib (AZD9291)

    Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

  • Lapatinib

    Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

  • AG-490 (Tyrphostin B42)

    AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.

  • Rociletinib (CO-1686, AVL-301)

    Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT in cell-free assays, respectively. Phase 2.

  • AG-1478 (Tyrphostin AG-1478)

    AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Recently Viewed Items

Tags: buy Gefitinib (ZD1839) | Gefitinib (ZD1839) ic50 | Gefitinib (ZD1839) price | Gefitinib (ZD1839) cost | Gefitinib (ZD1839) solubility dmso | Gefitinib (ZD1839) purchase | Gefitinib (ZD1839) manufacturer | Gefitinib (ZD1839) research buy | Gefitinib (ZD1839) order | Gefitinib (ZD1839) mouse | Gefitinib (ZD1839) chemical structure | Gefitinib (ZD1839) mw | Gefitinib (ZD1839) molecular weight | Gefitinib (ZD1839) datasheet | Gefitinib (ZD1839) supplier | Gefitinib (ZD1839) in vitro | Gefitinib (ZD1839) cell line | Gefitinib (ZD1839) concentration | Gefitinib (ZD1839) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us